Revision Index

805
====================================================================================================
Revision URL

https://en.wikipedia.org/w/index.php?title=CRISPR&oldid=723879518
====================================================================================================
Revision Section Tree

{'name': 'root',
 'level': 0,
 'parent': None,
 'path': 'root',
 'text': 'Clustered regularly interspaced short palindromic repeats (CRISPR, pronounced crisper[2]) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is '
         'followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid.[3]\n'
         '\n'
         'The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages,[4][5][6] and provides a form of '
         'acquired immunity. CRISPR spacers recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms.[3] CRISPRs are found in '
         'approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea.[7][note 1]\n'
         '\n'
         "By delivering the Cas9 nuclease and appropriate guide RNAs into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones "
         'added.[8][9][10] CRISPRs have been used in concert with specific endonuclease enzymes for genome editing and gene regulation in species throughout the tree of life.[11]\n'
         '\n'
         'Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida.[12][13] Other such systems are thought to exist.[14]\n'
         '\n'
         'The CRISPR interference technique has many potential applications, including altering the germline of humans, animals, including food crops. The use of CRISPR for genome editing[15][16] '
         "was the AAAS's choice for breakthrough of the year in 2015.[17] Ethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human "
         'germline.[18] \n'
         '\n'
         '1 History1.1 Cas91.2 Cpf11.3 Predecessors\n'
         '\n'
         '1.1 Cas9\n'
         '\n'
         '1.2 Cpf1\n'
         '\n'
         '1.3 Predecessors\n'
         '\n'
         '2 Locus structure2.1 Repeats and spacers2.2 Cas genes and CRISPR subtypes\n'
         '\n'
         '2.1 Repeats and spacers\n'
         '\n'
         '2.2 Cas genes and CRISPR subtypes\n'
         '\n'
         '3 Mechanism3.1 Spacer acquisition3.1.1 Protospacer adjacent motifs3.1.2 Insertion variants3.2 Interference3.2.1 Biogenesis3.2.2 Interference3.3 Delivery\n'
         '\n'
         '3.1 Spacer acquisition3.1.1 Protospacer adjacent motifs3.1.2 Insertion variants\n'
         '\n'
         '3.1.1 Protospacer adjacent motifs\n'
         '\n'
         '3.1.2 Insertion variants\n'
         '\n'
         '3.2 Interference3.2.1 Biogenesis3.2.2 Interference\n'
         '\n'
         '3.2.1 Biogenesis\n'
         '\n'
         '3.2.2 Interference\n'
         '\n'
         '3.3 Delivery\n'
         '\n'
         '4 Evolution and diversity\n'
         '\n'
         '5 Identification\n'
         '\n'
         '6 Evolutionary significance\n'
         '\n'
         '7 Use by phages\n'
         '\n'
         '8 Applications8.1 Genome engineering8.1.1 Major components8.1.2 Structure8.2 Editing8.3 Reversible knockdown8.4 Activation8.5 Disease models8.6 Gene drive8.7 Biomedicine8.8 Gene '
         'function8.9 In vitro genetic depletion\n'
         '\n'
         '8.1 Genome engineering8.1.1 Major components8.1.2 Structure\n'
         '\n'
         '8.1.1 Major components\n'
         '\n'
         '8.1.2 Structure\n'
         '\n'
         '8.2 Editing\n'
         '\n'
         '8.3 Reversible knockdown\n'
         '\n'
         '8.4 Activation\n'
         '\n'
         '8.5 Disease models\n'
         '\n'
         '8.6 Gene drive\n'
         '\n'
         '8.7 Biomedicine\n'
         '\n'
         '8.8 Gene function\n'
         '\n'
         '8.9 In vitro genetic depletion\n'
         '\n'
         '9 Patents and commercialization\n'
         '\n'
         '10 Society and culture10.1 Human germline modification10.2 Recognition\n'
         '\n'
         '10.1 Human germline modification\n'
         '\n'
         '10.2 Recognition\n'
         '\n'
         '11 See also\n'
         '\n'
         '12 Notes\n'
         '\n'
         '13 References\n'
         '\n'
         '14 Further reading',
 'subsections': [{'name': 'History',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|History',
                  'text': 'Clustered repeats were first described in 1987 for the bacterium Escherichia coli by Osaka University researcher Yoshizumi Ishino, but at that time their function was not '
                          'known.[19] The repeats were observed independently by Spanish researcher Francisco Mojica in 1993.[20] He later named them short regularly spaced repeats (SRSR) after he '
                          'found them in many other microbes.[21] In 2000, similar repeats were identified in other bacteria and archaea.[21] SRSR was renamed CRISPR in 2002 after a suggestion from '
                          'Mojica.[20][22] \n'
                          '\n'
                          'CRISPR was asserted to be responsible for the generation of adaptive immunity in microbes.[23] The paper describing this idea was initially rejected by high-profile '
                          'journals.[20] Papers proposing similar hypotheses by Gilles Vergnaud and independently by Alexander Bolotin initially suffered similar fates.[20][24][25]\n'
                          '\n'
                          'A set of genes was found to be associated with CRISPR repeats and was named Cas, or CRISPR-associated genes. The Cas genes encode putative nuclease or helicase proteins, '
                          'which are enzymes that can cut or unwind DNA, respectively.[22] \n'
                          '\n'
                          'In 2005, three independent research groups showed that some CRISPR spacers are derived from phage DNA and extrachromosomal DNA such as plasmids.[26][27][28] In effect, the '
                          'spacers are fragments of DNA gathered from viruses that previously tried to attack the cell. The source of the spacers was a sign that the CRISPR/cas system could have a '
                          'role in adaptive immunity in bacteria.[1][29] \n'
                          '\n'
                          'Koonin and colleagues proposed that spacers serve as a template for RNA molecules, analogous to the RNA interference system used by eukaryotic cells.[30]\n'
                          '\n'
                          "In 2007, Barrangou, Horvath (food industry scientists at Danisco), and Moineau's group at Université Laval (Canada) showed that they could use spacer DNA to alter the "
                          'resistance of Streptococcus thermophilus to phage attack.[30]\n'
                          '\n'
                          'Feng Zhang and colleagues first described genome editing in human and mouse cell culture using CRISPR/Cas systems.[31][32] It has since been used in a wide range of '
                          "organisms, including baker's yeast (Saccharomyces cerevisiae),[33] zebrafish (D. rerio),[34] fruit flies (Drosophila melanogaster),[35] axolotl (A. mexicanum),[36] "
                          'nematodes,(C. elegans),[37] plants,[38] mice,[39] monkeys[40] and human embryos.[41]\n'
                          '\n'
                          'CRISPR has been modified to make programmable transcription factors that allow scientists to target and activate or silence specific genes.[42]\n'
                          '\n'
                          'Libraries of tens of thousands of guide RNAs are available.[30]',
                  'subsections': [{'name': 'Cas9',
                                   'level': 2,
                                   'parent': 'History',
                                   'path': 'root|History|Cas9',
                                   'text': 'In 2012, Jennifer Doudna and Emmanuelle Charpentier first showed CRISPR to work as a genome-engineering and editing tool in bacterial cell '
                                           'cultures.[43][44][better\xa0source\xa0needed] The team had independently been exploring CRISPR-associated proteins to learn how bacteria use spacers in '
                                           'their immune defenses.[45][better\xa0source\xa0needed] They jointly studied a simpler CRISPR system that relies on a protein called Cas9. They found that '
                                           'bacteria respond to an invading phage by transcribing spacers and palindromic DNA into a long RNA molecule. The cell then uses tracrRNA and Cas9 to cut '
                                           'this long RNA molecule into pieces called crRNAs.[30]\n'
                                           '\n'
                                           "Cas9 is a nuclease, an enzyme specialized for cutting DNA. It has two active cutting sites (HNH and RuvC), one for each strand of the DNA's double helix. "
                                           "Doudna and Charpentier demonstrated that they could disable one or both sites while preserving Cas9's ability to home in on its target DNA. In 2012, a "
                                           'group including both Doudna and Charpentier combined tracrRNA and spacer RNA into a "single-guide RNA" molecule that, mixed with Cas9, could find and cut '
                                           'the correct DNA targets. Their study proposed that such synthetic guide RNAs could be used for gene editing.[43]',
                                   'subsections': []},
                                  {'name': 'Cpf1',
                                   'level': 2,
                                   'parent': 'History',
                                   'path': 'root|History|Cpf1',
                                   'text': 'In 2015, the nuclease Cpf1 was discovered in the CRISPR/Cpf1 system of Francisella novicida.[12][13]',
                                   'subsections': []},
                                  {'name': 'Predecessors',
                                   'level': 2,
                                   'parent': 'History',
                                   'path': 'root|History|Predecessors',
                                   'text': 'In the early 2000s, researchers developed zinc finger nucleases, synthetic proteins whose DNA-binding domains enable them to create double-stranded breaks '
                                           'in DNA at specific points. In 2010, synthetic nucleases called TALENs provided an easier way to target a double-stranded break to a specific location on '
                                           'the DNA strand. Both zinc finger nucleases and TALENs require the creation of a custom protein for each targeted DNA sequence, which is a more difficult '
                                           'and time-consuming process than that for guide RNAs. CRISPRs are much easier to design because the process requires making only a short RNA sequence.[46]',
                                   'subsections': []}]},
                 {'name': 'Locus structure',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Locus structure',
                  'text': '',
                  'subsections': [{'name': 'Repeats and spacers',
                                   'level': 2,
                                   'parent': 'Locus structure',
                                   'path': 'root|Locus structure|Repeats and spacers',
                                   'text': 'CRISPR repeats range in size from 24 to 48 base pairs.[47] They usually show some dyad symmetry, implying the formation of a secondary structure such as a '
                                           'hairpin, but are not truly palindromic.[48] Repeats are separated by spacers of similar length.[47] Some CRISPR spacer sequences exactly match sequences '
                                           "from plasmids and phages,[26][27][28] although some spacers match the prokaryote's genome (self-targeting spacers).[26][49] New spacers can be added "
                                           'rapidly as part of the immune response to phage infection.[50]',
                                   'subsections': []},
                                  {'name': 'Cas genes and CRISPR subtypes',
                                   'level': 2,
                                   'parent': 'Locus structure',
                                   'path': 'root|Locus structure|Cas genes and CRISPR subtypes',
                                   'text': 'Cas genes are often associated with CRISPR repeat-spacer arrays. Comparative genomics identified multiple cas genes; an initial analysis of 200 bacterial '
                                           'and archaeal genomes suggested as many as 45 cas gene families. Only cas1 and cas2 genes are present in all 45 families.[47]\n'
                                           '\n'
                                           'The current CRISPR classification groups cas operons into three major divisions: I, II, and III, each with multiple subdivisions based on case1 phylogeny '
                                           "and cas operon gene complement.[51] Aside from cas1 and cas2, each major division's operons have a common set of constituent genes. Each subdivision is "
                                           'characterised by a ‘signature gene’ found exclusively in that subdivision. Many organisms contain multiple CRISPR-Cas systems suggesting that they are '
                                           'compatible and may share components.[52][53] The sporadic distribution of the CRISPR/Cas subtypes suggests that the CRISPR/Cas system is subject to '
                                           'horizontal gene transfer during microbial evolution.',
                                   'subsections': []}]},
                 {'name': 'Mechanism',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Mechanism',
                  'text': 'CRISPR is part of a normally occurring bacterial process. Bacteria may incorporate foreign DNA and even scavenge damaged DNA from their environment.[63]',
                  'subsections': [{'name': 'Spacer acquisition',
                                   'level': 2,
                                   'parent': 'Mechanism',
                                   'path': 'root|Mechanism|Spacer acquisition',
                                   'text': 'When a microbe is invaded by a virus, the first stage of the immune response is to capture viral DNA and insert it into a CRISPR locus in the form of a '
                                           'spacer. Cas1 and Cas2 are found in all three types of CRISPR-Cas immune systems, which indicates that they are involved in spacer acquisition. Mutation '
                                           'studies confirmed this hypothesis, showing that removal of cas1 or cas2 stopped spacer acquisition, without affecting CRISPR immune '
                                           'response.[56][64][65][66][67]\n'
                                           '\n'
                                           'Multiple Cas1 proteins have been characterised and their structures resolved.[68][69][70] Cas1 proteins have diverse amino acid sequences. However, their '
                                           'crystal structures are similar and all purified Cas1 proteins are metal-dependent nucleases/integrases that bind to DNA in a sequence-independent '
                                           'manner.[52] Representative Cas2 proteins have been characterised and possess either ssRNA-[71] or dsDNA-[72][73] specific endoribonuclease activity.\n'
                                           '\n'
                                           'In the I-E system of E. coli Cas1 and Cas2 form a complex where a Cas2 dimer bridges two Cas1 dimers.[74] In this complex Cas2 performs a non-enzymatic '
                                           'scaffolding role,[74] binding double-stranded fragments of invading DNA, while Cas1 binds the single-stranded flanks of the DNA and catalyses their '
                                           'integration into CRISPR arrays.[75][76][77]',
                                   'subsections': [{'name': 'Protospacer adjacent motifs',
                                                    'level': 3,
                                                    'parent': 'Spacer acquisition',
                                                    'path': 'root|Mechanism|Spacer acquisition|Protospacer adjacent motifs',
                                                    'text': 'Bioinformatic analysis of regions of phage genomes that were excised as spacers (termed protospacers) revealed that they were not '
                                                            'randomly selected but instead were found adjacent to short (3 – 5 bp) DNA sequences termed protospacer adjacent motifs (PAM). Analysis of '
                                                            'CRISPR-Cas systems from the three major divisions showed PAMs to be important for type I and type II, but not type III systems during '
                                                            'acquisition.[28][78][79][80][81][82] In type I and type II systems, protospacers are excised at positions adjacent to a PAM sequence, '
                                                            'with the other end of the spacer cut using a ruler mechanism, thus maintaining the regularity of the spacer size in the CRISPR '
                                                            'array.[83][84] The conservation of the PAM sequence differs between CRISPR-Cas systems and appears to be evolutionarily linked to Cas1 '
                                                            'and the leader sequence.[82][85]\n'
                                                            '\n'
                                                            'New spacers are added to a CRISPR array in a directional manner,[26] occurring preferentially,[50][78][79][86][87] but not exclusively, '
                                                            'adjacent[81][84] to the leader sequence. Analysis of the type I-E system from E. coli demonstrated that the first direct repeat, adjacent '
                                                            'to the leader sequence is copied, with the newly acquired spacer inserted between the first and second direct repeats.[66][83]\n'
                                                            '\n'
                                                            'The PAM sequence appears to be important during spacer insertion in type I-E systems. That sequence contains a strongly conserved final '
                                                            'nucleotide (nt) adjacent to the first nucleotide of the protospacer. This nucleotide becomes the final base in the first direct '
                                                            'repeat.[67][88][89] This suggests that the spacer acquisition machinery generates single-stranded overhangs in the second-to-last '
                                                            'position of the direct repeat and in the PAM during spacer insertion. However, not all CRISPR-Cas systems appear to share this mechanism '
                                                            'as PAMs characterised in other organisms do not show the same level of conservation in the final position.[85] It is likely that in those '
                                                            'systems, a blunt end is generated at the very end of the direct repeat and the protospacer during acquisition.',
                                                    'subsections': []},
                                                   {'name': 'Insertion variants',
                                                    'level': 3,
                                                    'parent': 'Spacer acquisition',
                                                    'path': 'root|Mechanism|Spacer acquisition|Insertion variants',
                                                    'text': 'Analysis of Sulfolobus solfataricus CRISPRs revealed further complexities to the canonical model of spacer insertion as one of its six '
                                                            'CRISPR loci inserted new spacers randomly throughout its CRISPR array, as opposed to inserting closest to the leader sequence.[84]\n'
                                                            '\n'
                                                            'Multiple CRISPRs contain many spacers to the same phage. The mechanism that causes this phenomenon was elucidated in the type I-E system '
                                                            'of E. coli. A significant enhancement in spacer acquisition was detected where spacers already target the phage, even mismatches to the '
                                                            'protospacer. This ‘priming’ requires the Cas proteins involved in both acquisition and interference to interact with each other. Newly '
                                                            'acquired spacers that result from the priming mechanism are always found on the same strand as the spacer that caused the '
                                                            'priming.[67][88][89] This observation led to the hypothesis that the acquisition machinery slides along the foreign DNA after priming to '
                                                            'find a new protospacer.[89]',
                                                    'subsections': []}]},
                                  {'name': 'Interference',
                                   'level': 2,
                                   'parent': 'Mechanism',
                                   'path': 'root|Mechanism|Interference',
                                   'text': 'The CRISPR immune response occurs through two steps: CRISPR-RNA (crRNA) biogenesis and crRNA-guided interference.',
                                   'subsections': [{'name': 'Biogenesis',
                                                    'level': 3,
                                                    'parent': 'Interference',
                                                    'path': 'root|Mechanism|Interference|Biogenesis',
                                                    'text': 'The crRNA is initially transcribed as part of a single long transcript encompassing much of the CRISPR array.[3] This transcript is then '
                                                            'cleaved by Cas proteins to form crRNAs. The mechanism to produce crRNAs differs among CRISPR-Cas systems. In type I-E and type I-F '
                                                            'systems, the proteins Cas6e and Cas6f respectively, recognise stem-loops[90][91][92] created by the pairing of identical repeats which '
                                                            'flank the crRNA.[48] These Cas proteins cleave the longer transcript at the edge of the paired region, leaving a single crRNA along with '
                                                            'a small remnant of the paired repeat region.\n'
                                                            '\n'
                                                            'Type III systems also use Cas6, however their repeats do not produce stem-loops. Cleavage instead occurs by the longer transcript '
                                                            'wrapping around the Cas6 to allow cleavage just upstream of the repeat sequence.[93][94][95]\n'
                                                            '\n'
                                                            'Type II systems lack the Cas6 gene and instead utilize RNaseIII for cleavage. Functional type II systems encode an extra small RNA that '
                                                            'is complementary to the repeat sequence, known as a trans-activating crRNA (tracrRNA).[64] Transcription of the tracrRNA and the primary '
                                                            'CRISPR transcript results in base pairing and the formation of dsRNA at the repeat sequence, which is subsequently targeted by RNaseIII '
                                                            'to produce crRNAs. Unlike the other two systems the crRNA does not contain the full spacer but instead is truncated at one end.[59]\n'
                                                            '\n'
                                                            'CrRNAs associate with Cas proteins to form ribonucleotide complexes that recognize foreign nucleic acids. CrRNAs show no preference '
                                                            'between the coding and non-coding strands, which is indicative of an RNA-guided DNA-targeting system.[6][56][67][96][97][98][99] The type '
                                                            'I-E complex (commonly referred to as Cascade) requires five Cas proteins bound to a single crRNA.[100][101]',
                                                    'subsections': []},
                                                   {'name': 'Interference',
                                                    'level': 3,
                                                    'parent': 'Interference',
                                                    'path': 'root|Mechanism|Interference|Interference',
                                                    'text': 'During the interference stage in type I systems the PAM sequence is recognized on the crRNA-complementary strand and is required along '
                                                            'with crRNA annealing. In type I systems correct base pairing between the crRNA and the protospacer signals a conformational change in '
                                                            'Cascade that recruits Cas3 for DNA degradation.\n'
                                                            '\n'
                                                            'Type II systems rely on a single multifunctional protein, Cas9, for the interference step.[59] Cas9 requires both the crRNA and the '
                                                            'tracrRNA to function and cleaves DNA using its dual HNH and RuvC/RNaseH-like endonuclease domains. Basepairing between the PAM and the '
                                                            'phage genome is also required in type II systems, however the PAM is recognized on the same strand as the crRNA (the opposite strand to '
                                                            'type I systems).\n'
                                                            '\n'
                                                            'Type III systems, like type I require six or seven Cas proteins binding to crRNAs.[102][103] The type III systems analysed from S. '
                                                            'solfataricus and P. furiosus both target the mRNA of phages rather than phage DNA genome,[53][103] which may make these systems uniquely '
                                                            'capable of targeting RNA-based phage genomes.[52]\n'
                                                            '\n'
                                                            'The mechanism for distinguishing self from foreign DNA during interference is built into the crRNAs and is therefore likely common to all '
                                                            'three systems. Throughout the distinctive maturation process of each major type, all crRNAs contain a spacer sequence and some portion of '
                                                            'the repeat at one or both ends. It is the partial repeat sequence that prevents the CRISPR-Cas system from targeting the chromosome as '
                                                            'base pairing beyond the spacer sequence signals self and prevents DNA cleavage.[104] RNA-guided CRISPR enzymes are classified as type V '
                                                            'restriction enzymes.',
                                                    'subsections': []}]},
                                  {'name': 'Delivery',
                                   'level': 2,
                                   'parent': 'Mechanism',
                                   'path': 'root|Mechanism|Delivery',
                                   'text': 'Scientists can use viral or non-viral system for delivery of the Cas9 and gRNA into target cells. Electroporation of DNA, RNA or ribonucleocomplexes is '
                                           'the most common and cheapest system. This technique was used to edit CXCR4 and PD-1, knocking in new sequences to replace specific genetic “letters” in '
                                           'these proteins. The group was then able to sort the cells, using cell surface markers, to help identify successfully edited cells.[105] Deep sequencing of '
                                           'a target site confirmed that knock-in genome modifications had occurred with up to ∼20% efficiency, which accounted for up to approximately one-third of '
                                           'total editing events.[106] However, hard-to-transfect cells (stem cells, neurons, hematopoietic cells, etc.) require more efficient delivery systems such '
                                           'as those based on lentivirus (LVs), adenovirus (AdV) and adenoassociated (AAV).',
                                   'subsections': []}]},
                 {'name': 'Evolution and diversity',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Evolution and diversity',
                  'text': 'The basic model of CRISPR evolution is one where newly incorporated spacers drive phages to mutate their genomes to avoid the bacteria immune response, creating diversity '
                          'in both the phage and host populations. To fight off a phage infection, the sequence of the CRISPR spacer must correspond perfectly to the sequence of the target phage '
                          'gene. Phages can continue to infect their hosts given point mutations in the spacer.[104] Similar stringency is required in PAM or the bacterial strain will remain phage '
                          'sensitive.[79][104]\n'
                          '\n'
                          'A study of 124 S. thermophilus strains showed that 26% of all spacers were unique and that different CRISPR loci showed different rates of new spacer acquisition.[78] '
                          "Particular CRISPR loci evolve more rapidly than others, which allowed the strains' phylogenetic relationships to be determined. A comparative genomic analysis showed that "
                          "E. coli and S. enterica evolve much more slowly than S. thermophilus. The latter's strains that had diverged 250 thousand years ago still contained the same spacer "
                          'complement.[107]\n'
                          '\n'
                          'Metagenomic analysis of two acid mine drainage biofilms showed that one of the analyzed CRISPRs contained extensive deletions and spacer additions in comparison to the '
                          'other biofilm, suggesting a higher phage activity/prevalence in one community compared to the other.[50] In the oral cavity, a temporal study determined that 7-22% of '
                          'spacers were shared over 17 months within an individual while less than 2% of spacers were shared between individuals.[87]\n'
                          '\n'
                          'From the same environment a single strain was tracked using PCR primers specific to its CRISPR system. Unlike the broad-level results of spacer presence/absence, which '
                          'showed significant diversity, this CRISPR added 3 spacers over 17 months,[87] suggesting that even in an environment with significant CRISPR diversity some loci evolve '
                          'slowly. CRISPRs have also been analysed from the metagenomes produced for the human microbiome project.[108] Although most CRISPRs were body-site specific, some CRISPRs '
                          'within a body site are widely shared among individuals. One of these CRISPR loci originated from streptococcal species and contained ~15,000 spacers, 50% of which were '
                          'unique. Similar to the targeted studies of the oral cavity, some of the CRISPRs showed little evolution over time.[108]\n'
                          '\n'
                          'CRISPR evolution has been studied in chemostats using S. thermophilus to explicitly examine spacer acquisition rates. In one week, S. thermophilus strains acquired up to '
                          'three spacers when challenged with a single phage.[109] During the same interval the phage developed single nucleotide polymorphisms that became fixed in the population, '
                          'suggesting that CRISPR targeting had prevented phage replication absent these mutations.[109] Other S. thermophilus experiments showed that phages can still infect and '
                          'replicate in hosts that have only one targeting spacer and that sensitive hosts can exist in environments with high phage titres.[110] The chemostat and observational '
                          'studies suggest many nuances to CRISPR and phage (co)evolution.',
                  'subsections': []},
                 {'name': 'Identification',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Identification',
                  'text': 'CRISPRs are widely distributed among bacteria and archaea[51] and show some sequence similarities.[48] However their most notable characteristic is their repeating spacers '
                          'and direct repeats. This characteristic makes CRISPRs easily identifiable in long sequences of DNA, since the number of repeat copies decreases the likelihood of a false '
                          'positive match. Three programs are used for CRISPR repeat identification that search for regularly interspaced repeats in long sequences: CRT,[111] PILER-CR[112] and '
                          'CRISPRfinder.[113]\n'
                          '\n'
                          'Analysis of CRISPRs in metagenomic data is more challenging, as CRISPR loci do not typically assemble due to their repetitive nature or through strain variation, which '
                          'confuses assembly algorithms. Where many reference genomes are available, polymerase chain reaction (PCR) can be used to amplify CRISPR arrays and analyse spacer '
                          'content.[78][87][114][115][116] However, this approach yields information only for specifically targeted CRISPRs and for organisms with sufficient representation in public '
                          'databases to design reliable PCR primers.\n'
                          '\n'
                          'The alternative is to extract and reconstruct CRISPR arrays from shotgun metagenomic data. This is computationally more difficult, particularly with second generation '
                          'sequencing technologies (e.g. 454, Illumina), as the short read lengths prevent more than two or three repeat units appearing in a single read. CRISPR identification in '
                          'raw reads has been achieved using purely denovo identification[117] or by using direct repeat sequences in partially assembled CRISPR arrays from contigs (overlapping DNA '
                          'segments that together represent a consensus region of DNA)[108] and direct repeat sequences from published genomes[118] as a hook for identifying direct repeats in '
                          'individual reads.',
                  'subsections': []},
                 {'name': 'Evolutionary significance',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Evolutionary significance',
                  'text': 'A bioinformatic study showed that CRISPRs are evolutionarily conserved and cluster into related types. Many show signs of a conserved secondary structure.[48]\n'
                          '\n'
                          'Through the CRISPR/Cas mechanism, bacteria can acquire immunity to certain phages and thus halt further transmission of targeted phages. For this reason, Eugene Koonin has '
                          'described CRISPR/Cas as a Lamarckian inheritance mechanism.[119] However, this has been disputed by a recent critic noting "We should remember [Lamarck] for the good he '
                          'contributed to science, not for things that resemble his theory only superficially. Indeed, thinking of CRISPR and other phenomena as Lamarckian only obscures the simple '
                          'and elegant way evolution really works.[120]\n'
                          '\n'
                          'Analysis of CRISPR sequences revealed coevolution of host and viral genomes.[121] Cas9 proteins are highly enriched in pathogenic and commensal bacteria. '
                          'CRISPR/Cas-mediated gene regulation may contribute to the regulation of endogenous bacterial genes, particularly during interaction with eukaryotic hosts. For example, '
                          'Francisella novicida uses a unique, small, CRISPR/Cas-associated RNA (scaRNA) to repress an endogenous transcript encoding a bacterial lipoprotein that is critical for F. '
                          'novicida to dampen host response and promote virulence.[122]',
                  'subsections': []},
                 {'name': 'Use by phages',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Use by phages',
                  'text': 'Another way for bacteria to defend against phage infection is by having chromosomal islands. A subtype of chromosomal islands called phage-inducible chromosomal island '
                          '(PICI) is excised from a bacterial chromosome upon phage infection and can inhibit phage replication.[123] The mechanisms that induce PICI excision and how PICI inhibits '
                          'phage replication are not well understood. One study showed that lytic ICP1 phage, which specifically targets Vibrio cholerae serogroup O1, has acquired a CRISPR/Cas '
                          'system that targets a V. cholera PICI-like element. The system has 2 CRISPR loci and 9 Cas genes. It seems to be homologous to the 1-F system found in Yersinia pestis. '
                          'Moreover, like the bacterial CRISPR/Cas system, ICP1 CRISPR/Cas can acquire new sequences, which allows phage and host to co-evolve.[124]',
                  'subsections': []},
                 {'name': 'Applications',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Applications',
                  'text': 'By the end of 2014 some 600 research papers had been published that mentioned CRISPR.[125] The technology has been used to functionally inactivate genes in human cell '
                          'lines and cells, to study Candida albicans, to modify yeasts used to make biofuels and to genetically modify crop strains.[125]',
                  'subsections': [{'name': 'Genome engineering',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Genome engineering',
                                   'text': 'CRISPR/Cas9 genome editing is carried out with a Type II CRISPR system. When utilized for genome editing, this system includes Cas9, CRISPR RNA (crRNA), '
                                           'trans-activating crRNA (tracrRNA) along with an optional section of DNA repair template that is utilized in either Non-Homologous End Joining (NHEJ) or '
                                           'Homology Directed Repair (HDR).',
                                   'subsections': [{'name': 'Major components',
                                                    'level': 3,
                                                    'parent': 'Genome engineering',
                                                    'path': 'root|Applications|Genome engineering|Major components',
                                                    'text': 'CRISPR/Cas9 often employs a plasmid to transfect the target cells. The main components of this plasmid are displayed in the image and '
                                                            'listed in the table. The crRNA needs to be designed for each application as this is the sequence that Cas9 uses to identify and directly '
                                                            "bind to the cell's DNA. The crRNA must bind only where editing is desired. The repair template must also be designed for each "
                                                            'application, as it must overlap with the sequences on either side of the cut and code for the insertion sequence.\n'
                                                            '\n'
                                                            "Multiple crRNA's and the tracrRNA can be packaged together to form a single-guide RNA (sgRNA). This sgRNA can be joined together with the "
                                                            'Cas9 gene and made into a plasmid in order to be transfected into cells (see image for overview).',
                                                    'subsections': []},
                                                   {'name': 'Structure',
                                                    'level': 3,
                                                    'parent': 'Genome engineering',
                                                    'path': 'root|Applications|Genome engineering|Structure',
                                                    'text': 'CRISPR/Cas9 is a widely used system for genome editing due to its high degree of fidelity and relatively simple construction. CRISPR/Cas9 '
                                                            'depends on two factors for its specificity – the CRISPR target sequence and the PAM. The CRISPR target sequence is 20 bases long as part '
                                                            'of each CRISPR locus in the crRNA array.[128] A typical crRNA array has multiple unique target sequences. Cas9 proteins select the '
                                                            "correct location on the host's genome by utilizing the sequence for base pair bonding with the host DNA. The sequence is not part of the "
                                                            'Cas9 protein and as a result is customizable and can be independently synthesized.[129][130]\n'
                                                            '\n'
                                                            'The PAM sequence on the host genome is recognized by the protein structure of Cas9 and generally cannot be easily modified to recognize a '
                                                            'difference sequence. However this is not too limiting as it is a short sequence and not very specific (e.g. the SpCas9 PAM sequence is '
                                                            "5'-NGG-3' and in the human genome occurs roughly every 8 to 12 base pairs).[128]\n"
                                                            '\n'
                                                            'Once these have been assembled into a plasmid and transfected into cells the Cas9 protein with help of the crRNA finds the correct '
                                                            "sequence in the host cell's DNA and – depending on the Cas9 variant – creates a single or double strand break in the DNA. Properly spaced "
                                                            'single strand breaks in the host DNA can trigger homology directed repair, which is less error prone than non-homologous end joining that '
                                                            'typically follows a double strand break. Providing a section of DNA repair template allows for the insertion of a specific DNA sequence '
                                                            'at an exact location within the genome. The repair template should extend 40 to 90 base pairs beyond the Cas9 induced DNA break.[128] The '
                                                            "goal is for the cell's HDR process to utilize the provided repair template and thereby incorporate the new sequence into the genome. Once "
                                                            "incorporated, this new sequence is now part of the cell's genetic material and passes into its daughter cells.\n"
                                                            '\n'
                                                            'Many online tools are available to aid in designing effective sgRNA sequences.[131]',
                                                    'subsections': []}]},
                                  {'name': 'Editing',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Editing',
                                   'text': 'CRISPRs have been used to cut five[30] to 62 genes at once: pig cells have been engineered to inactivate all 62 Porcine Endogenous Retrovirus in the pig '
                                           "genome, which eliminated infection from the pig to human cells in culture.[132] CRISPR's low cost compared to alternatives is widely seen as "
                                           'revolutionary.[8][9]\n'
                                           '\n'
                                           'Selective engineered redirection of the CRISPR/Cas system was first demonstrated in 2012 in:[133][134]\n'
                                           '\n'
                                           'Immunization of industrially important bacteria, including some used in food production and large-scale fermentation\n'
                                           '\n'
                                           'Cellular or organism RNA-guided genome engineering. Proof of concept studies demonstrated examples both in vitro[10][43][59] and in vivo[39][135][136]\n'
                                           '\n'
                                           'Bacterial strain discrimination by comparison of spacer sequences',
                                   'subsections': []},
                                  {'name': 'Reversible knockdown',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Reversible knockdown',
                                   'text': 'Like RNAi, CRISPR interference (CRISPRi) turns off genes in a reversible fashion by targeting, but not cutting a site. The targeted site is methylated so '
                                           'the gene is epigenetically modified. This modification inhibits transcription. Cas9 is an effective way of targeting and silencing specific genes at the '
                                           'DNA level.[137] In bacteria, the presence of Cas9 alone is enough to block transcription. For mammalian applications, a section of protein is added. Its '
                                           'guide RNA targets regulatory DNA sequences called promoters that immediately precede the target gene.[30]',
                                   'subsections': []},
                                  {'name': 'Activation',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Activation',
                                   'text': 'Cas9 was used to carry synthetic transcription factors that activated specific human genes. The technique achieved a strong effect by targeting multiple '
                                           "CRISPR constructs to slightly different locations on the gene's promoter.[30]\n"
                                           '\n'
                                           'Some of the affected genes are tied to human diseases, including those involved in muscle differentiation, cancer, inflammation and fetal hemoglobin.[30]',
                                   'subsections': []},
                                  {'name': 'Disease models',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Disease models',
                                   'text': 'CRISPR simplifies creation of animals for research that mimic disease or show what happens when a gene is knocked down or mutated. CRISPR may be used at '
                                           'the germline level to create animals where the gene is changed everywhere, or it may be locally targeted.[138][139][140]\n'
                                           '\n'
                                           'CRISPR can also be utilized to create human cellular models of disease. For instance, CRISPR was applied to human pluripotent stem cells to introduce '
                                           'targeted mutations in genes relevant to two different kidney diseases, polycystic kidney disease and focal segmental glomerulosclerosis.[141] These '
                                           'CRISPR-modified pluripotent stem cells were subsequently grown into human kidney organoids, which exhibited disease-specific phenotypes. Kidney organoids '
                                           'from stem cells with polycystic kidney disease mutations formed large, translucent cyst structures from kidney tubules. Kidney organoids with mutations in '
                                           'a gene linked to focal segmental glomerulosclerosis developed junctional defects between podocytes, the filtering cells affected in that disease. '
                                           'Importantly, these disease phenotypes were absent in control organoids of identical genetic background, but lacking the CRISPR mutations.[141] A similar '
                                           'approach has been taken to model long QT syndrome in cardiomyocytes derived from pluripotent stem cells.[142] These CRISPR-generated cellular models, with '
                                           'isogenic controls, provide a new way to study human diseases and test drugs that might work in human patients.',
                                   'subsections': []},
                                  {'name': 'Gene drive',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Gene drive',
                                   'text': 'In 2003 evolutionary biologist Austin Burt envisioned attaching a gene that coded for a desired trait to “selfish” DNA elements that could copy themselves '
                                           'from one chromosome position to another. That would bias daughter cells to inherit it, quickly spreading it throughout a population. In 2015 a U.S. team '
                                           'used CRISPR to create a “mutagenic chain reaction” that drove a pigmentation trait in lab-grown Drosophila to the next generation with 97% efficiency. '
                                           'With another research group they created a gene drive in mosquitoes that spread genes that prevented the insects from harboring malaria parasites. Only '
                                           'weeks later, the team reported a second drive with genes that rendered female mosquitoes infertile and could quickly wipe out a population. The work was '
                                           'done in the lab, leading to debates over the desirability of field testing.[143]',
                                   'subsections': []},
                                  {'name': 'Biomedicine',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Biomedicine',
                                   'text': 'Using “dead” versions of Cas9 (dCas9) eliminates CRISPR’s DNA-cutting ability, while preserving its ability to target desirable sequences. Multiple groups '
                                           'added various regulatory factors to dCas9s, enabling them to turn almost any gene on or off or subtly adjust its level of activity.[143]\n'
                                           '\n'
                                           'CRISPR/Cas-based "RNA-guided nucleases" can be used to target virulence factors, genes encoding antibiotic resistance, and other medically relevant '
                                           'sequences of interest. This technology thus represents a novel form of antimicrobial therapy and a strategy by which to manipulate bacterial '
                                           'populations.[144]\n'
                                           '\n'
                                           'In another 2015 experiment, the 20,000 or so known human genes were separately targeted, turning them on one by one in groups of cells to identify those '
                                           'involved in resistance to a melanoma drug. Each such gene manipulation is itself a separate "drug", potentially opening the entire genome to CRISPR-based '
                                           'regulation.[143]\n'
                                           '\n'
                                           'Clinical researchers are applying it to develop tissue-based treatments for cancer and other diseases.[143]\n'
                                           '\n'
                                           'CRISPR may revive the concept of transplanting animal organs into people. Retroviruses present in animal genomes could harm transplant recipients. In 2015 '
                                           'a team eliminated 62 copies of a retrovirus’s DNA from the pig genome.[143]\n'
                                           '\n'
                                           'It may also have applications in tissue engineering and regenerative medicine, such as by creating human blood vessels that lack expression of MHC class '
                                           'II proteins, which often cause transplant rejection.[145]',
                                   'subsections': []},
                                  {'name': 'Gene function',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|Gene function',
                                   'text': 'In 2015, multiple studies attempted to systematically disable every individual human gene, in an attempt to identify which genes were essential. Between '
                                           '1,600 and 1,800 genes passed their test—around one in ten. Such genes are more strongly activated, and unlikely to carry disabling mutations. They are '
                                           'more likely to have indispensable counterparts in other species. They build proteins that unite to form larger collaborative complexes. The specific '
                                           'functions of some 18 percent of the essential genes are unidentified. The studies also catalogued the essential genes in four cancer-cell lines and '
                                           'identified genes that are expendable in healthy cells, but crucial in specific tumor types and drugs that could target these rogue genes.[146]',
                                   'subsections': []},
                                  {'name': 'In vitro genetic depletion',
                                   'level': 2,
                                   'parent': 'Applications',
                                   'path': 'root|Applications|In vitro genetic depletion',
                                   'text': 'Unenriched sequencing libraries often have abundant undesired sequences. Cas9 can specifically deplete the undesired sequences with double strand breakage '
                                           'with up to 99% efficiency and without significant off-target effects as seen with restriction enzymes. Treatment with Cas9 has can deplete abundant rRNA '
                                           'while increasing pathogen sensitivity in RNA-seq libraries.[147]',
                                   'subsections': []}]},
                 {'name': 'Patents and commercialization',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Patents and commercialization',
                  'text': 'As of December 2014, patent rights to CRISPR were contested. Several companies had been formed to develop related drugs and research tools.[148] As companies ramp up '
                          'financing, doubts as to whether or not CRISPR can be successfully monetized in the short-term have been raised.[149]\n'
                          '\n'
                          'As of November 2013, SAGE Labs (now part of Horizon Discovery group) had exclusive rights from one of those companies to produce and sell genetically engineered rats and '
                          'non-exclusive rights for mouse and rabbit models.[150]',
                  'subsections': []},
                 {'name': 'Society and culture',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Society and culture',
                  'text': '',
                  'subsections': [{'name': 'Human germline modification',
                                   'level': 2,
                                   'parent': 'Society and culture',
                                   'path': 'root|Society and culture|Human germline modification',
                                   'text': 'In light of plans or ongoing research to apply CRISPR to human embryos in at least four labs in the US, labs in China and the UK, and by a US '
                                           'biotechnology company called Ovascience,[151] scientists, including an inventor of CRISPR, urged a worldwide moratorium on applying CRISPR to the human '
                                           'germline, especially for clinical use. They said "scientists should avoid even attempting, in lax jurisdictions, germline genome modification for clinical '
                                           'application in humans" until the full implications "are discussed among scientific and governmental organizations".[41][152] These scientists support '
                                           'basic research on CRISPR and do not see CRISPR as developed enough for any clinical use in making inheritable changes to people.[153]\n'
                                           '\n'
                                           'In April 2015, scientists from China published a paper in the journal Protein & Cell reporting results of an attempt to alter the DNA of non-viable human '
                                           "embryos using CRISPR to correct a mutation that causes beta thalassemia, a lethal heritable disorder.[154][155] According to the paper's lead author, the "
                                           'study had previously been rejected by both Nature and Science in part because of ethical concerns; the journals did not comment to reporters.[156] The '
                                           'experiments resulted in changing only some of the genes, and had off-target effects on other genes. The scientists who conducted the research stated that '
                                           'CRISPR is not ready for clinical application in reproductive medicine. One said to a reporter at Nature: "If you want to do it in normal embryos, you need '
                                           'to be close to 100%.... That’s why we stopped. We still think it’s too immature."[156]\n'
                                           '\n'
                                           'In December 2015, the International Summit on Human Gene Editing took place in Washington under the guidance of David Baltimore. Members of national '
                                           'scientific academies of America, Britain and China discussed the ethics of germline modification. In conclusion, they agreed to proceed further with basic '
                                           'and clinical research under appropriate legal and ethical guidelines. A specific distinction was made between clinical use in somatic cells, where the '
                                           'effects of edits are limited to a single individual, versus germline cells, where genome changes would be inherited by future generations. This could have '
                                           'unintended and far-reaching consequences for human evolution, genetically (e.g. gene/environment interactions) and culturally (e.g. Social Darwinism), '
                                           'hence altering of gametocytes and embryos to generate inheritable changes in humans was claimed irresponsible. In addition, they agreed to initiate an '
                                           'international forum where these concerns will be continuously addressed, and regulations in research harmonised across countries.[157]\n'
                                           '\n'
                                           'In February 2016, British scientists were given permission by regulators to genetically modify human embryos by using CRISPR-Cas9 and related techniques. '
                                           'The embryos were to be destroyed after seven days.[158][159]',
                                   'subsections': []},
                                  {'name': 'Recognition',
                                   'level': 2,
                                   'parent': 'Society and culture',
                                   'path': 'root|Society and culture|Recognition',
                                   'text': 'American Jennifer Doudna and French-born Emmanuelle Charpentier co-authored a key study published in August 2012 that demonstrated the technical power of '
                                           'Crispr-Cas9 to cut and splice genes with extreme efficiency at the highest resolution possible. In 2012 and 2013, CRISPR was a runner-up in Science '
                                           "Magazine's Breakthrough of the Year award. In 2015, it was the winner of that award.[143] CRISPR was also named as one of MIT Technology Review's 10 "
                                           'breakthroughs technologies in 2014 and 2016.[160][161]\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR2: Secondary structure taken from the Rfam database. Family RF01315.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR2: Secondary structure taken from the Rfam database. Family RF01315.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR5: Secondary structure taken from the Rfam database. Family RF011318.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR5: Secondary structure taken from the Rfam database. Family RF011318.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR6: Secondary structure taken from the Rfam database. Family RF01319.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR6: Secondary structure taken from the Rfam database. Family RF01319.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR8: Secondary structure taken from the Rfam database. Family RF01321.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR8: Secondary structure taken from the Rfam database. Family RF01321.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR9: Secondary structure taken from the Rfam database. Family RF01322.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR9: Secondary structure taken from the Rfam database. Family RF01322.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR19: Secondary structure taken from the Rfam database. Family RF01332.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR19: Secondary structure taken from the Rfam database. Family RF01332.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR41: Secondary structure taken from the Rfam database. Family RF01350.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR41: Secondary structure taken from the Rfam database. Family RF01350.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR52: Secondary structure taken from the Rfam database. Family RF01365.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR52: Secondary structure taken from the Rfam database. Family RF01365.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR57: Secondary structure taken from the Rfam database. Family RF01370.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR57: Secondary structure taken from the Rfam database. Family RF01370.\n'
                                           '\n'
                                           '\t\t\t\t\t\tCRISPR-DR65: Secondary structure taken from the Rfam database. Family RF01378.\t\t\t\t\t\n'
                                           '\n'
                                           'CRISPR-DR65: Secondary structure taken from the Rfam database. Family RF01378.',
                                   'subsections': []}]},
                 {'name': 'See also',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|See also',
                  'text': 'Cas9\n'
                          '\n'
                          'CRISPR/Cas Tools\n'
                          '\n'
                          'CRISPR/Cpf1\n'
                          '\n'
                          'CRISPR interference\n'
                          '\n'
                          'Gene drive\n'
                          '\n'
                          'Gene knockout\n'
                          '\n'
                          'Gene silencing\n'
                          '\n'
                          'Protospacer adjacent motif\n'
                          '\n'
                          'RNAi\n'
                          '\n'
                          'SiRNA\n'
                          '\n'
                          'Transcription activator-like effector nuclease (TALEN)\n'
                          '\n'
                          'Zinc finger nuclease\n'
                          '\n'
                          'Bioterrorism\n'
                          '\n'
                          'Biological warfare\n'
                          '\n'
                          'Synthetic Biology\n'
                          '\n'
                          'Surveyor Nuclease Assay',
                  'subsections': []},
                 {'name': 'Notes',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Notes',
                  'text': '^ 71/79 Archaea, 463/1008 Bacteria CRISPRdb, Date: 19.6.2010 Template:Wayback\n\n[162]',
                  'subsections': []},
                 {'name': 'References',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|References',
                  'text': '^ a b c .mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\\"""\\"""\'""\'"}.mw-parser-output .id-lock-free a,.mw-parser-output '
                          '.citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation '
                          '.cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription '
                          'a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px '
                          'no-repeat}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration '
                          'span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon '
                          'a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px '
                          'no-repeat}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output '
                          '.cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output '
                          '.cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output '
                          '.cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation '
                          '.mw-selflink{font-weight:inherit}Horvath P, Barrangou R (January 2010). "CRISPR/Cas, the immune system of bacteria and archaea". Science. 327 (5962): 167–70. '
                          'Bibcode:2010Sci...327..167H. doi:10.1126/Science.1179555. PMID\xa020056882.\n'
                          '\n'
                          '^ Sawyer, Eric (9 February 2013). "Editing Genomes with the Bacterial Immune System". Scitable. Nature Publishing Group. Retrieved 6 April 2015.\n'
                          '\n'
                          '^ a b c d Marraffini LA, Sontheimer EJ (March 2010). "CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea". Nature Reviews. Genetics. 11 (3): '
                          '181–90. doi:10.1038/nrg2749. PMC\xa02928866. PMID\xa020125085. \n'
                          '\n'
                          '^ Redman M, King A, Watson C, King D (April 2016). "What is CRISPR/Cas9?". Archives of Disease in Childhood. Education and Practice Edition. '
                          'doi:10.1136/archdischild-2016-310459. PMID\xa027059283.\n'
                          '\n'
                          '^ Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P (March 2007). "CRISPR provides acquired resistance against viruses in '
                          'prokaryotes". Science. 315 (5819): 1709–12. Bibcode:2007Sci...315.1709B. doi:10.1126/science.1138140. PMID\xa017379808. (registration required)\n'
                          '\n'
                          '^ a b Marraffini LA, Sontheimer EJ (December 2008). "CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA". Science. 322 (5909): 1843–5. '
                          'Bibcode:2008Sci...322.1843M. doi:10.1126/science.1165771. PMC\xa02695655. PMID\xa019095942.\n'
                          '\n'
                          '^ a b Grissa I, Vergnaud G, Pourcel C (2007). "The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats". BMC Bioinformatics. '
                          '8: 172. doi:10.1186/1471-2105-8-172. PMC\xa01892036. PMID\xa017521438.\n'
                          '\n'
                          '^ a b Ledford, Heidi (3 June 2015). "CRISPR, the disruptor". News Feature. Nature. 522 (7554).\n'
                          '\n'
                          '^ a b Snyder, Bill (21 August 2014). "New technique accelerates genome editing process". research news @ Vanderbilt. Nashville, Tennessee: Vanderbilt University.\n'
                          '\n'
                          '^ a b Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, Bruhn L, Porteus MH '
                          '(September 2015). "Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells". Nature Biotechnology. 33 (9): 985–9. doi:10.1038/nbt.3290. '
                          'PMID\xa026121415. \n'
                          '\n'
                          '^ Mali P, Esvelt KM, Church GM (October 2013). "Cas9 as a versatile tool for engineering biology". Nature Methods. 10 (10): 957–63. doi:10.1038/nmeth.2649. PMC\xa04051438. '
                          'PMID\xa024076990.\n'
                          '\n'
                          '^ a b Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (October 2015). '
                          '"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system". Cell. 163 (3): 759–71. doi:10.1016/j.cell.2015.09.038. PMID\xa026422227. PMID 26422227.\n'
                          '\n'
                          '^ a b Fonfara I, Richter H, Bratovič M, Le Rhun A, Charpentier E (April 2016). "The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA". '
                          'Nature. 532 (7600): 517–21. doi:10.1038/nature17945. PMID\xa027096362. PMID 27096362.\n'
                          '\n'
                          '^ "Even CRISPR". The Economist. ISSN\xa00013-0613. Retrieved 2016-05-25.\n'
                          '\n'
                          '^ Ledford, Heidi (2016-03-10). "CRISPR: gene editing is just the beginning". Nature. 531 (7593): 156–159. doi:10.1038/531156a.\n'
                          '\n'
                          '^ Maxmen, Amy (August 2015). "The Genesis Engine". WIRED. Retrieved 2016-06-05.\n'
                          '\n'
                          '^ 2015 Breakthrough of the Year, Science Magazine, American Association for the Advancement of Science, 2016,\n'
                          '\n'
                          '^ Ledford H (June 2015). "CRISPR, the disruptor". Nature. 522 (7554): 20–4. doi:10.1038/522020a. PMID\xa026040877.\n'
                          '\n'
                          '^ Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (December 1987). "Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in '
                          'Escherichia coli, and identification of the gene product". Journal of Bacteriology. 169 (12): 5429–33. PMC\xa0213968. PMID\xa03316184.\n'
                          '\n'
                          '^ a b c d Lander ES (January 2016). "The Heroes of CRISPR". Cell. 164 (1–2): 18–28. doi:10.1016/j.cell.2015.12.041. PMID\xa026771483.\n'
                          '\n'
                          '^ a b Mojica FJ, Díez-Villaseñor C, Soria E, Juez G (April 2000). "Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and '
                          'mitochondria". Molecular Microbiology. 36 (1): 244–6. doi:10.1046/j.1365-2958.2000.01838.x. PMID\xa010760181.\n'
                          '\n'
                          '^ a b Jansen R, Embden JD, Gaastra W, Schouls LM (March 2002). "Identification of genes that are associated with DNA repeats in prokaryotes". Molecular Microbiology. 43 '
                          '(6): 1565–75. doi:10.1046/j.1365-2958.2002.02839.x. PMID\xa011952905.\n'
                          '\n'
                          '^ Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E (February 2005). "Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic '
                          'elements". Journal of Molecular Evolution. 60 (2): 174–82. doi:10.1007/s00239-004-0046-3. PMID\xa015791728.\n'
                          '\n'
                          '^ Pourcel C, Salvignol G, Vergnaud G (March 2005). "CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide '
                          'additional tools for evolutionary studies". Microbiology. 151 (Pt 3): 653–63. doi:10.1099/mic.0.27437-0. PMID\xa015758212.\n'
                          '\n'
                          '^ Bolotin A, Quinquis B, Sorokin A, Ehrlich SD (August 2005). "Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin". '
                          'Microbiology. 151 (Pt 8): 2551–61. doi:10.1099/mic.0.28048-0. PMID\xa016079334.\n'
                          '\n'
                          '^ a b c d Pourcel C, Salvignol G, Vergnaud G (March 2005). "CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide '
                          'additional tools for evolutionary studies". Microbiology. 151 (Pt 3): 653–63. doi:10.1099/mic.0.27437-0. PMID\xa015758212.\n'
                          '\n'
                          '^ a b Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E (February 2005). "Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic '
                          'elements". Journal of Molecular Evolution. 60 (2): 174–82. doi:10.1007/s00239-004-0046-3. PMID\xa015791728.\n'
                          '\n'
                          '^ a b c Bolotin A, Quinquis B, Sorokin A, Ehrlich SD (August 2005). "Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal '
                          'origin". Microbiology. 151 (Pt 8): 2551–61. doi:10.1099/mic.0.28048-0. PMID\xa016079334.\n'
                          '\n'
                          '^ Morange M (June 2015). "What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes". Journal of Biosciences. 40 (2): 221–3. '
                          'doi:10.1007/s12038-015-9532-6. PMID\xa025963251.\n'
                          '\n'
                          '^ a b c d e f g h Pennisi E (August 2013). "The CRISPR craze". News Focus. Science. 341 (6148): 833–6. doi:10.1126/science.341.6148.833. PMID\xa023970676.\n'
                          '\n'
                          '^ Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (February 2013). "Multiplex genome engineering using CRISPR/Cas '
                          'systems". Science. 339 (6121): 819–23. doi:10.1126/science.1231143. PMC\xa03795411. PMID\xa023287718.\n'
                          '\n'
                          '^ Zhang, Feng (Aug 21, 2014), CRISPR-CAS Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes, retrieved 2016-04-26\n'
                          '\n'
                          '^ DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM (April 2013). "Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems". Nucleic Acids '
                          'Research. 41 (7): 4336–43. doi:10.1093/nar/gkt135. PMC\xa03627607. PMID\xa023460208.\n'
                          '\n'
                          '^ Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK (March 2013). "Efficient genome editing in zebrafish using a CRISPR-Cas system". '
                          'Nature Biotechnology. 31 (3): 227–9. doi:10.1038/nbt.2501. PMC\xa03686313. PMID\xa023360964.\n'
                          '\n'
                          '^ Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, O\'Connor-Giles KM (August 2013). "Genome engineering of Drosophila with the CRISPR '
                          'RNA-guided Cas9 nuclease". Genetics. 194 (4): 1029–35. doi:10.1534/genetics.113.152710. PMC\xa03730909. PMID\xa023709638.\n'
                          '\n'
                          '^ Flowers GP, Timberlake AT, McLean KC, Monaghan JR, Crews CM (May 2014). "Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease". Development. '
                          '141 (10): 2165–71. doi:10.1242/dev.105072. PMC\xa04011087. PMID\xa024764077.\n'
                          '\n'
                          '^ Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA (August 2013). "Heritable genome editing in C. elegans via a CRISPR-Cas9 system". Nature Methods. '
                          '10 (8): 741–3. doi:10.1038/nmeth.2532. PMC\xa03822328. PMID\xa023817069.\n'
                          '\n'
                          '^ Jiang W, Zhou H, Bi H, Fromm M, Yang B, Weeks DP (November 2013). "Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, '
                          'sorghum and rice". Nucleic Acids Research. 41 (20): e188. doi:10.1093/nar/gkt780. PMC\xa03814374. PMID\xa023999092.\n'
                          '\n'
                          '^ a b Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, Jaenisch R (May 2013). "One-step generation of mice carrying mutations in multiple genes by '
                          'CRISPR/Cas-mediated genome engineering". Cell. 153 (4): 910–8. doi:10.1016/j.cell.2013.04.025. PMID\xa023643243.\n'
                          '\n'
                          '^ Guo X, Li XJ (July 2015). "Targeted genome editing in primate embryos". Cell Research. 25 (7): 767–8. doi:10.1038/cr.2015.64. PMID\xa026032266.\n'
                          '\n'
                          '^ a b Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M, Greely HT, Jinek M, Martin GS, Penhoet E, Puck J, Sternberg '
                          'SH, Weissman JS, Yamamoto KR (April 2015). "Biotechnology. A prudent path forward for genomic engineering and germline gene modification". Science. 348 (6230): 36–8. '
                          'Bibcode:2015Sci...348...36B. doi:10.1126/science.aab1028. PMID\xa025791083.\n'
                          '\n'
                          '^ Larson MH, Gilbert LA, Wang X, Lim WA, Weissman JS, Qi LS (November 2013). "CRISPR interference (CRISPRi) for sequence-specific control of gene expression". Nature '
                          'Protocols. 8 (11): 2180–96. doi:10.1038/nprot.2013.132. PMID\xa024136345.\n'
                          '\n'
                          '^ a b c Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (August 2012). "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity". '
                          'Science. 337 (6096): 816–21. Bibcode:2012Sci...337..816J. doi:10.1126/science.1225829. PMID\xa022745249.\n'
                          '\n'
                          '^ Connor S (7 November 2013). "CRISPR gene therapy: Scientists call for more public debate around breakthrough technique". Science. London: The Independent. Retrieved '
                          '2013-11-25.\n'
                          '\n'
                          '^ Pollack A (11 May 2015). "Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing". The New York Times. Retrieved 12 May 2015.\n'
                          '\n'
                          '^ Young S (11 February 2014). "CRISPR and Other Genome Editing Tools Boost Medical Research and Gene Therapy\'s Reach". MIT Technology Review. Cambridge, Massachusetts: '
                          'Massachusetts Institute of Technology. Retrieved 2014-04-13.\n'
                          '\n'
                          '^ a b c Haft DH, Selengut J, Mongodin EF, Nelson KE (November 2005). "A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in '
                          'prokaryotic genomes". PLoS Computational Biology. 1 (6): e60. Bibcode:2005PLSCB...1...60H. doi:10.1371/journal.pcbi.0010060. PMC\xa01282333. PMID\xa016292354.\n'
                          '\n'
                          '^ a b c d Kunin V, Sorek R, Hugenholtz P (2007). "Evolutionary conservation of sequence and secondary structures in CRISPR repeats". Genome Biology. 8 (4): R61. '
                          'doi:10.1186/gb-2007-8-4-r61. PMC\xa01896005. PMID\xa017442114.\n'
                          '\n'
                          '^ Stern A, Keren L, Wurtzel O, Amitai G, Sorek R (August 2010). "Self-targeting by CRISPR: gene regulation or autoimmunity?". Trends in Genetics. 26 (8): 335–40. '
                          'doi:10.1016/j.tig.2010.05.008. PMC\xa02910793. PMID\xa020598393.\n'
                          '\n'
                          '^ a b c Tyson GW, Banfield JF (January 2008). "Rapidly evolving CRISPRs implicated in acquired resistance of microorganisms to viruses". Environmental Microbiology. 10 '
                          '(1): 200–7. doi:10.1111/j.1462-2920.2007.01444.x. PMID\xa017894817.\n'
                          '\n'
                          '^ a b c Chylinski K, Makarova KS, Charpentier E, Koonin EV (June 2014). "Classification and evolution of type II CRISPR-Cas systems". Nucleic Acids Research. 42 (10): '
                          '6091–105. doi:10.1093/nar/gku241. PMC\xa04041416. PMID\xa024728998.\n'
                          '\n'
                          '^ a b c Wiedenheft B, Sternberg SH, Doudna JA (February 2012). "RNA-guided genetic silencing systems in bacteria and archaea". Nature. 482 (7385): 331–8. '
                          'Bibcode:2012Natur.482..331W. doi:10.1038/nature10886. PMID\xa022337052.\n'
                          '\n'
                          '^ a b Deng L, Garrett RA, Shah SA, Peng X, She Q (March 2013). "A novel interference mechanism by a type IIIB CRISPR-Cmr module in Sulfolobus". Molecular Microbiology. 87 '
                          '(5): 1088–99. doi:10.1111/mmi.12152. PMID\xa023320564.\n'
                          '\n'
                          '^ Sinkunas T, Gasiunas G, Fremaux C, Barrangou R, Horvath P, Siksnys V (April 2011). "Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas '
                          'immune system". The EMBO Journal. 30 (7): 1335–42. doi:10.1038/emboj.2011.41. PMC\xa03094125. PMID\xa021343909.\n'
                          '\n'
                          '^ Huo Y, Nam KH, Ding F, Lee H, Wu L, Xiao Y, Farchione MD, Zhou S, Rajashankar K, Kurinov I, Zhang R, Ke A (September 2014). "Structures of CRISPR Cas3 offer mechanistic '
                          'insights into Cascade-activated DNA unwinding and degradation". Nature Structural & Molecular Biology. 21 (9): 771–7. doi:10.1038/nsmb.2875. PMC\xa04156918. PMID\xa0'
                          '25132177.\n'
                          '\n'
                          '^ a b c Aliyari R, Ding SW (January 2009). "RNA-based viral immunity initiated by the Dicer family of host immune receptors". Immunological Reviews. 227 (1): 176–88. '
                          'doi:10.1111/j.1600-065X.2008.00722.x. PMC\xa02676720. PMID\xa019120484.\n'
                          '\n'
                          '^ Cass SD, Haas KA, Stoll B, Alkhnbashi O, Sharma K, Urlaub H, Backofen R, Marchfelder A, Bolt EL (May 2015). "The role of Cas8 in type I CRISPR interference". Bioscience '
                          'Reports. 35 (3). doi:10.1042/BSR20150043. PMID\xa025940458.\n'
                          '\n'
                          '^ a b Makarova KS, Aravind L, Wolf YI, Koonin EV (2011). "Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems". '
                          'Biology Direct. 6: 38. doi:10.1186/1745-6150-6-38. PMC\xa03150331. PMID\xa021756346.\n'
                          '\n'
                          '^ a b c d Gasiunas G, Barrangou R, Horvath P, Siksnys V (September 2012). "Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in '
                          'bacteria". Proceedings of the National Academy of Sciences of the United States of America. 109 (39): E2579-86. Bibcode:2012PNAS..109E2579G. doi:10.1073/pnas.1208507109. '
                          'PMC\xa03465414. PMID\xa022949671.\n'
                          '\n'
                          '^ Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, Marraffini LA (March 2015). "Cas9 specifies functional viral targets during CRISPR-Cas adaptation". Nature. '
                          '519 (7542): 199–202. Bibcode:2015Natur.519..199H. doi:10.1038/nature14245. PMC\xa04385744. PMID\xa025707807.\n'
                          '\n'
                          '^ Nam KH, Kurinov I, Ke A (September 2011). "Crystal structure of clustered regularly interspaced short palindromic repeats (CRISPR)-associated Csn2 protein revealed '
                          'Ca2+-dependent double-stranded DNA binding activity". The Journal of Biological Chemistry. 286 (35): 30759–68. doi:10.1074/jbc.M111.256263. PMC\xa03162437. PMID\xa0'
                          '21697083.\n'
                          '\n'
                          '^ Chylinski K, Le Rhun A, Charpentier E (May 2013). "The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems". RNA Biology. 10 (5): 726–37. '
                          'doi:10.4161/rna.24321. PMC\xa03737331. PMID\xa023563642.\n'
                          '\n'
                          '^ Overballe-Petersen S, Harms K, Orlando LA, Mayar JV, Rasmussen S, Dahl TW, Rosing MT, Poole AM, Sicheritz-Ponten T, Brunak S, Inselmann S, de Vries J, Wackernagel W, '
                          'Pybus OG, Nielsen R, Johnsen PJ, Nielsen KM, Willerslev E (December 2013). "Bacterial natural transformation by highly fragmented and damaged DNA". Proceedings of the '
                          'National Academy of Sciences of the United States of America. 110 (49): 19860–5. Bibcode:2013PNAS..11019860O. doi:10.1073/pnas.1315278110. PMID\xa024248361. Lay summary – '
                          'Kurzweil (19 November 2013).\n'
                          '\n'
                          '^ a b Dugar G, Herbig A, Förstner KU, Heidrich N, Reinhardt R, Nieselt K, Sharma CM (May 2013). "High-resolution transcriptome maps reveal strain-specific regulatory '
                          'features of multiple Campylobacter jejuni isolates". PLoS Genetics. 9 (5): e1003495. doi:10.1371/journal.pgen.1003495. PMC\xa03656092. PMID\xa023696746.\n'
                          '\n'
                          '^ Hatoum-Aslan A, Maniv I, Marraffini LA (December 2011). "Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler '
                          'mechanism anchored at the precursor processing site". Proceedings of the National Academy of Sciences of the United States of America. 108 (52): 21218–22. '
                          'Bibcode:2011PNAS..10821218H. doi:10.1073/pnas.1112832108. PMC\xa03248500. PMID\xa022160698.\n'
                          '\n'
                          '^ a b Yosef I, Goren MG, Qimron U (July 2012). "Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli". Nucleic Acids Research. 40 '
                          '(12): 5569–76. doi:10.1093/nar/gks216. PMC\xa03384332. PMID\xa022402487.\n'
                          '\n'
                          '^ a b c d Swarts DC, Mosterd C, van Passel MW, Brouns SJ (2012). "CRISPR interference directs strand specific spacer acquisition". PloS One. 7 (4): e35888. '
                          'Bibcode:2012PLoSO...735888S. doi:10.1371/journal.pone.0035888. PMC\xa03338789. PMID\xa022558257.\n'
                          '\n'
                          '^ Babu M, Beloglazova N, Flick R, Graham C, Skarina T, Nocek B, Gagarinova A, Pogoutse O, Brown G, Binkowski A, Phanse S, Joachimiak A, Koonin EV, Savchenko A, Emili A, '
                          'Greenblatt J, Edwards AM, Yakunin AF (January 2011). "A dual function of the CRISPR-Cas system in bacterial antivirus immunity and DNA repair". Molecular Microbiology. 79 '
                          '(2): 484–502. doi:10.1111/j.1365-2958.2010.07465.x. PMC\xa03071548. PMID\xa021219465.\n'
                          '\n'
                          '^ Han D, Lehmann K, Krauss G (June 2009). "SSO1450--a CAS1 protein from Sulfolobus solfataricus P2 with high affinity for RNA and DNA". FEBS Letters. 583 (12): 1928–32. '
                          'doi:10.1016/j.febslet.2009.04.047. PMID\xa019427858.\n'
                          '\n'
                          '^ Wiedenheft B, Zhou K, Jinek M, Coyle SM, Ma W, Doudna JA (June 2009). "Structural basis for DNase activity of a conserved protein implicated in CRISPR-mediated genome '
                          'defense". Structure. 17 (6): 904–12. doi:10.1016/j.str.2009.03.019. PMID\xa019523907.\n'
                          '\n'
                          '^ Beloglazova N, Brown G, Zimmerman MD, Proudfoot M, Makarova KS, Kudritska M, Kochinyan S, Wang S, Chruszcz M, Minor W, Koonin EV, Edwards AM, Savchenko A, Yakunin AF '
                          '(July 2008). "A novel family of sequence-specific endoribonucleases associated with the clustered regularly interspaced short palindromic repeats". The Journal of '
                          'Biological Chemistry. 283 (29): 20361–71. doi:10.1074/jbc.M803225200. PMC\xa02459268. PMID\xa018482976.\n'
                          '\n'
                          '^ Samai P, Smith P, Shuman S (December 2010). "Structure of a CRISPR-associated protein Cas2 from Desulfovibrio vulgaris". Acta Crystallographica. Section F, Structural '
                          'Biology and Crystallization Communications. 66 (Pt 12): 1552–6. doi:10.1107/S1744309110039801. PMC\xa02998353. PMID\xa021139194.\n'
                          '\n'
                          '^ Nam KH, Ding F, Haitjema C, Huang Q, DeLisa MP, Ke A (October 2012). "Double-stranded endonuclease activity in Bacillus halodurans clustered regularly interspaced short '
                          'palindromic repeats (CRISPR)-associated Cas2 protein". The Journal of Biological Chemistry. 287 (43): 35943–52. doi:10.1074/jbc.M112.382598. PMC\xa03476262. PMID\xa0'
                          '22942283.\n'
                          '\n'
                          '^ a b Nuñez JK, Kranzusch PJ, Noeske J, Wright AV, Davies CW, Doudna JA (June 2014). "Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive '
                          'immunity". Nature Structural & Molecular Biology. 21 (6): 528–34. doi:10.1038/nsmb.2820. PMC\xa04075942. PMID\xa024793649.\n'
                          '\n'
                          '^ Nuñez JK, Lee AS, Engelman A, Doudna JA (March 2015). "Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity". Nature. 519 (7542): 193–8. '
                          'doi:10.1038/nature14237. PMC\xa04359072. PMID\xa025707795.\n'
                          '\n'
                          '^ Wang J, Li J, Zhao H, Sheng G, Wang M, Yin M, Wang Y (November 2015). "Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems". Cell. '
                          '163 (4): 840–53. doi:10.1016/j.cell.2015.10.008. PMID\xa026478180.\n'
                          '\n'
                          '^ Nuñez JK, Harrington LB, Kranzusch PJ, Engelman AN, Doudna JA (November 2015). "Foreign DNA capture during CRISPR-Cas adaptive immunity". Nature. 527 (7579): 535–8. '
                          'doi:10.1038/nature15760. PMID\xa026503043.\n'
                          '\n'
                          '^ a b c d Horvath P, Romero DA, Coûté-Monvoisin AC, Richards M, Deveau H, Moineau S, Boyaval P, Fremaux C, Barrangou R (February 2008). "Diversity, activity, and evolution '
                          'of CRISPR loci in Streptococcus thermophilus". Journal of Bacteriology. 190 (4): 1401–12. doi:10.1128/JB.01415-07. PMC\xa02238196. PMID\xa018065539.\n'
                          '\n'
                          '^ a b c Deveau H, Barrangou R, Garneau JE, Labonté J, Fremaux C, Boyaval P, Romero DA, Horvath P, Moineau S (February 2008). "Phage response to CRISPR-encoded resistance '
                          'in Streptococcus thermophilus". Journal of Bacteriology. 190 (4): 1390–400. doi:10.1128/JB.01412-07. PMC\xa02238228. PMID\xa018065545.\n'
                          '\n'
                          '^ Mojica FJ, Díez-Villaseñor C, García-Martínez J, Almendros C (March 2009). "Short motif sequences determine the targets of the prokaryotic CRISPR defence system". '
                          'Microbiology. 155 (Pt 3): 733–40. doi:10.1099/mic.0.023960-0. PMID\xa019246744.\n'
                          '\n'
                          '^ a b Lillestøl RK, Shah SA, Brügger K, Redder P, Phan H, Christiansen J, Garrett RA (April 2009). "CRISPR families of the crenarchaeal genus Sulfolobus: bidirectional '
                          'transcription and dynamic properties". Molecular Microbiology. 72 (1): 259–72. doi:10.1111/j.1365-2958.2009.06641.x. PMID\xa019239620.\n'
                          '\n'
                          '^ a b Shah SA, Hansen NR, Garrett RA (February 2009). "Distribution of CRISPR spacer matches in viruses and plasmids of crenarchaeal acidothermophiles and implications for '
                          'their inhibitory mechanism". Biochemical Society Transactions. 37 (Pt 1): 23–8. doi:10.1042/BST0370023. PMID\xa019143596.\n'
                          '\n'
                          '^ a b Díez-Villaseñor C, Guzmán NM, Almendros C, García-Martínez J, Mojica FJ (May 2013). "CRISPR-spacer integration reporter plasmids reveal distinct genuine acquisition '
                          'specificities among CRISPR-Cas I-E variants of Escherichia coli". RNA Biology. 10 (5): 792–802. doi:10.4161/rna.24023. PMC\xa03737337. PMID\xa023445770.\n'
                          '\n'
                          '^ a b c Erdmann S, Garrett RA (September 2012). "Selective and hyperactive uptake of foreign DNA by adaptive immune systems of an archaeon via two distinct mechanisms". '
                          'Molecular Microbiology. 85 (6): 1044–56. doi:10.1111/j.1365-2958.2012.08171.x. PMC\xa03468723. PMID\xa022834906.\n'
                          '\n'
                          '^ a b Shah SA, Erdmann S, Mojica FJ, Garrett RA (May 2013). "Protospacer recognition motifs: mixed identities and functional diversity". RNA Biology. 10 (5): 891–9. '
                          'doi:10.4161/rna.23764. PMC\xa03737346. PMID\xa023403393.\n'
                          '\n'
                          '^ Andersson AF, Banfield JF (May 2008). "Virus population dynamics and acquired virus resistance in natural microbial communities". Science. 320 (5879): 1047–50. '
                          'Bibcode:2008Sci...320.1047A. doi:10.1126/science.1157358. PMID\xa018497291.\n'
                          '\n'
                          '^ a b c d Pride DT, Sun CL, Salzman J, Rao N, Loomer P, Armitage GC, Banfield JF, Relman DA (January 2011). "Analysis of streptococcal CRISPRs from human saliva reveals '
                          'substantial sequence diversity within and between subjects over time". Genome Research. 21 (1): 126–36. doi:10.1101/gr.111732.110. PMC\xa03012920. PMID\xa021149389.\n'
                          '\n'
                          '^ a b Goren MG, Yosef I, Auster O, Qimron U (October 2012). "Experimental definition of a clustered regularly interspaced short palindromic duplicon in Escherichia coli". '
                          'Journal of Molecular Biology. 423 (1): 14–6. doi:10.1016/j.jmb.2012.06.037. PMID\xa022771574.\n'
                          '\n'
                          '^ a b c Datsenko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E (2012). "Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial '
                          'immunity system". Nature Communications. 3: 945. Bibcode:2012NatCo...3E.945D. doi:10.1038/ncomms1937. PMID\xa022781758.\n'
                          '\n'
                          '^ Gesner EM, Schellenberg MJ, Garside EL, George MM, Macmillan AM (June 2011). "Recognition and maturation of effector RNAs in a CRISPR interference pathway". Nature '
                          'Structural & Molecular Biology. 18 (6): 688–92. doi:10.1038/nsmb.2042. PMID\xa021572444.\n'
                          '\n'
                          '^ Sashital DG, Jinek M, Doudna JA (June 2011). "An RNA-induced conformational change required for CRISPR RNA cleavage by the endoribonuclease Cse3". Nature Structural & '
                          'Molecular Biology. 18 (6): 680–7. doi:10.1038/nsmb.2043. PMID\xa021572442.\n'
                          '\n'
                          '^ Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA (September 2010). "Sequence- and structure-specific RNA processing by a CRISPR endonuclease". Science. 329 (5997): '
                          '1355–8. Bibcode:2010Sci...329.1355H. doi:10.1126/science.1192272. PMC\xa03133607. PMID\xa020829488.\n'
                          '\n'
                          '^ Carte J, Wang R, Li H, Terns RM, Terns MP (December 2008). "Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes". Genes & '
                          'Development. 22 (24): 3489–96. doi:10.1101/gad.1742908. PMC\xa02607076. PMID\xa019141480.\n'
                          '\n'
                          '^ Wang R, Preamplume G, Terns MP, Terns RM, Li H (February 2011). "Interaction of the Cas6 riboendonuclease with CRISPR RNAs: recognition and cleavage". Structure. 19 (2): '
                          '257–64. doi:10.1016/j.str.2010.11.014. PMC\xa03154685. PMID\xa021300293.\n'
                          '\n'
                          '^ Niewoehner O, Jinek M, Doudna JA (January 2014). "Evolution of CRISPR RNA recognition and processing by Cas6 endonucleases". Nucleic Acids Research. 42 (2): 1341–53. '
                          'doi:10.1093/nar/gkt922. PMC\xa03902920. PMID\xa024150936.\n'
                          '\n'
                          '^ Garneau JE, Dupuis MÈ, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magadán AH, Moineau S (November 2010). "The CRISPR/Cas bacterial immune system '
                          'cleaves bacteriophage and plasmid DNA". Nature. 468 (7320): 67–71. Bibcode:2010Natur.468...67G. doi:10.1038/nature09523. PMID\xa021048762.\n'
                          '\n'
                          '^ Semenova E, Jore MM, Datsenko KA, Semenova A, Westra ER, Wanner B, van der Oost J, Brouns SJ, Severinov K (June 2011). "Interference by clustered regularly interspaced '
                          'short palindromic repeat (CRISPR) RNA is governed by a seed sequence". Proceedings of the National Academy of Sciences of the United States of America. 108 (25): '
                          '10098–103. Bibcode:2011PNAS..10810098S. doi:10.1073/pnas.1104144108. PMC\xa03121866. PMID\xa021646539.\n'
                          '\n'
                          '^ Gudbergsdottir S, Deng L, Chen Z, Jensen JV, Jensen LR, She Q, Garrett RA (January 2011). "Dynamic properties of the Sulfolobus CRISPR/Cas and CRISPR/Cmr systems when '
                          'challenged with vector-borne viral and plasmid genes and protospacers". Molecular Microbiology. 79 (1): 35–49. doi:10.1111/j.1365-2958.2010.07452.x. PMC\xa03025118. '
                          'PMID\xa021166892.\n'
                          '\n'
                          '^ Manica A, Zebec Z, Teichmann D, Schleper C (April 2011). "In vivo activity of CRISPR-mediated virus defence in a hyperthermophilic archaeon". Molecular Microbiology. 80 '
                          '(2): 481–91. doi:10.1111/j.1365-2958.2011.07586.x. PMID\xa021385233.\n'
                          '\n'
                          '^ Jore MM, Lundgren M, van Duijn E, Bultema JB, Westra ER, Waghmare SP, Wiedenheft B, Pul U, Wurm R, Wagner R, Beijer MR, Barendregt A, Zhou K, Snijders AP, Dickman MJ, '
                          'Doudna JA, Boekema EJ, Heck AJ, van der Oost J, Brouns SJ (May 2011). "Structural basis for CRISPR RNA-guided DNA recognition by Cascade". Nature Structural & Molecular '
                          'Biology. 18 (5): 529–36. doi:10.1038/nsmb.2019. PMID\xa021460843.\n'
                          '\n'
                          '^ Wiedenheft B, Lander GC, Zhou K, Jore MM, Brouns SJ, van der Oost J, Doudna JA, Nogales E (September 2011). "Structures of the RNA-guided surveillance complex from a '
                          'bacterial immune system". Nature. 477 (7365): 486–9. Bibcode:2011Natur.477..486W. doi:10.1038/nature10402. PMID\xa021938068.\n'
                          '\n'
                          '^ Zhang J, Rouillon C, Kerou M, Reeks J, Brugger K, Graham S, Reimann J, Cannone G, Liu H, Albers SV, Naismith JH, Spagnolo L, White MF (February 2012). "Structure and '
                          'mechanism of the CMR complex for CRISPR-mediated antiviral immunity". Molecular Cell. 45 (3): 303–13. doi:10.1016/j.molcel.2011.12.013. PMC\xa03381847. PMID\xa022227115.\n'
                          '\n'
                          '^ a b Hale CR, Zhao P, Olson S, Duff MO, Graveley BR, Wells L, Terns RM, Terns MP (November 2009). "RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex". Cell. 139 '
                          '(5): 945–56. doi:10.1016/j.cell.2009.07.040. PMC\xa02951265. PMID\xa019945378.\n'
                          '\n'
                          '^ a b c Marraffini LA, Sontheimer EJ (January 2010). "Self versus non-self discrimination during CRISPR RNA-directed immunity". Nature. 463 (7280): 568–71. '
                          'Bibcode:2010Natur.463..568M. doi:10.1038/nature08703. PMC\xa02813891. PMID\xa020072129.\n'
                          '\n'
                          '^ "Scientists successfully edit human immune-system T cells | KurzweilAI". www.kurzweilai.net. Retrieved 2016-01-01.\n'
                          '\n'
                          '^ Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A (August 2015). "Generation of knock-in primary '
                          'human T cells using Cas9 ribonucleoproteins". Proceedings of the National Academy of Sciences of the United States of America. 112 (33): 10437–42. '
                          'doi:10.1073/pnas.1512503112. PMC\xa04547290. PMID\xa026216948.\n'
                          '\n'
                          '^ Touchon M, Rocha EP (2010). Randau L (ed.). "The small, slow and specialized CRISPR and anti-CRISPR of Escherichia and Salmonella". PloS One. 5 (6): e11126. '
                          'Bibcode:2010PLoSO...511126T. doi:10.1371/journal.pone.0011126. PMC\xa02886076. PMID\xa020559554.\n'
                          '\n'
                          '^ a b c Rho M, Wu YW, Tang H, Doak TG, Ye Y (2012). "Diverse CRISPRs evolving in human microbiomes". PLoS Genetics. 8 (6): e1002441. doi:10.1371/journal.pgen.1002441. '
                          'PMC\xa03374615. PMID\xa022719260.\n'
                          '\n'
                          '^ a b Sun CL, Barrangou R, Thomas BC, Horvath P, Fremaux C, Banfield JF (February 2013). "Phage mutations in response to CRISPR diversification in a bacterial population". '
                          'Environmental Microbiology. 15 (2): 463–70. doi:10.1111/j.1462-2920.2012.02879.x. PMID\xa023057534.\n'
                          '\n'
                          '^ Kuno S, Sako Y, Yoshida T (May 2014). "Diversification of CRISPR within coexisting genotypes in a natural population of the bloom-forming cyanobacterium Microcystis '
                          'aeruginosa". Microbiology. 160 (Pt 5): 903–16. doi:10.1099/mic.0.073494-0. PMID\xa024586036.\n'
                          '\n'
                          '^ Bland C, Ramsey TL, Sabree F, Lowe M, Brown K, Kyrpides NC, Hugenholtz P (2007). "CRISPR recognition tool (CRT): a tool for automatic detection of clustered regularly '
                          'interspaced palindromic repeats". BMC Bioinformatics. 8: 209. doi:10.1186/1471-2105-8-209. PMC\xa01924867. PMID\xa017577412.\n'
                          '\n'
                          '^ Edgar RC (2007). "PILER-CR: fast and accurate identification of CRISPR repeats". BMC Bioinformatics. 8: 18. doi:10.1186/1471-2105-8-18. PMC\xa01790904. PMID\xa0'
                          '17239253.\n'
                          '\n'
                          '^ Grissa I, Vergnaud G, Pourcel C (July 2007). "CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats". Nucleic Acids Research. 35 '
                          '(Web Server issue): W52-7. doi:10.1093/nar/gkm360. PMC\xa01933234. PMID\xa017537822.\n'
                          '\n'
                          '^ Pride DT, Salzman J, Relman DA (September 2012). "Comparisons of clustered regularly interspaced short palindromic repeats and viromes in human saliva reveal bacterial '
                          'adaptations to salivary viruses". Environmental Microbiology. 14 (9): 2564–76. doi:10.1111/j.1462-2920.2012.02775.x. PMC\xa03424356. PMID\xa022583485.\n'
                          '\n'
                          '^ Held NL, Herrera A, Whitaker RJ (November 2013). "Reassortment of CRISPR repeat-spacer loci in Sulfolobus islandicus". Environmental Microbiology. 15 (11): 3065–76. '
                          'doi:10.1111/1462-2920.12146. PMID\xa023701169.\n'
                          '\n'
                          '^ Held NL, Herrera A, Cadillo-Quiroz H, Whitaker RJ (2010). "CRISPR associated diversity within a population of Sulfolobus islandicus". PloS One. 5 (9). '
                          'Bibcode:2010PLoSO...512988H. doi:10.1371/journal.pone.0012988. PMC\xa02946923. PMID\xa020927396.\n'
                          '\n'
                          '^ Skennerton CT, Imelfort M, Tyson GW (May 2013). "Crass: identification and reconstruction of CRISPR from unassembled metagenomic data". Nucleic Acids Research. 41 (10): '
                          'e105. doi:10.1093/nar/gkt183. PMC\xa03664793. PMID\xa023511966.\n'
                          '\n'
                          '^ Stern A, Mick E, Tirosh I, Sagy O, Sorek R (October 2012). "CRISPR targeting reveals a reservoir of common phages associated with the human gut microbiome". Genome '
                          'Research. 22 (10): 1985–94. doi:10.1101/gr.138297.112. PMC\xa03460193. PMID\xa022732228.\n'
                          '\n'
                          '^ Koonin EV, Wolf YI (2009). "Is evolution Darwinian or/and Lamarckian?". Biology Direct. 4: 42. doi:10.1186/1745-6150-4-42. PMC\xa02781790. PMID\xa019906303.\n'
                          '\n'
                          '^ Weiss A (October 2015). "Lamarckian Illusions". Trends in Ecology & Evolution. 30 (10): 566–8. doi:10.1016/j.tree.2015.08.003. PMID\xa026411613.\n'
                          '\n'
                          '^ Heidelberg JF, Nelson WC, Schoenfeld T, Bhaya D (2009). Ahmed N (ed.). "Germ warfare in a microbial mat community: CRISPRs provide insights into the co-evolution of host '
                          'and viral genomes". PloS One. 4 (1): e4169. Bibcode:2009PLoSO...4.4169H. doi:10.1371/journal.pone.0004169. PMC\xa02612747. PMID\xa019132092.\n'
                          '\n'
                          '^ Sampson TR, Saroj SD, Llewellyn AC, Tzeng YL, Weiss DS (May 2013). "A CRISPR/Cas system mediates bacterial innate immune evasion and virulence". Nature. 497 (7448): '
                          '254–7. Bibcode:2013Natur.497..254S. doi:10.1038/nature12048. PMC\xa03651764. PMID\xa023584588.\n'
                          '\n'
                          '^ Novick RP, Christie GE, Penadés JR (August 2010). "The phage-related chromosomal islands of Gram-positive bacteria". Nature Reviews. Microbiology. 8 (8): 541–51. '
                          'doi:10.1038/nrmicro2393. PMC\xa03522866. PMID\xa020634809.\n'
                          '\n'
                          '^ Seed KD, Lazinski DW, Calderwood SB, Camilli A (February 2013). "A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity". Nature. 494 '
                          '(7438): 489–91. Bibcode:2013Natur.494..489S. doi:10.1038/nature11927. PMC\xa03587790. PMID\xa023446421.\n'
                          '\n'
                          '^ a b Ledford H (June 2015). "CRISPR, the disruptor". Nature. 522 (7554): 20–4. Bibcode:2015Natur.522...20L. doi:10.1038/522020a. PMID\xa026040877.\n'
                          '\n'
                          '^ "CRISPR/Cas9 Plasmids". www.systembio.com. Retrieved 2015-12-17.\n'
                          '\n'
                          '^ "CRISPR Cas9 Genome Editing". www.origene.com. OriGene. Retrieved 2015-12-17.\n'
                          '\n'
                          '^ a b c d Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (November 2013). "Genome engineering using the CRISPR-Cas9 system". Nature Protocols. 8 (11): 2281–308. '
                          'doi:10.1038/nprot.2013.143. PMC\xa03969860. PMID\xa024157548.\n'
                          '\n'
                          '^ Horvath P, Barrangou R (January 2010). "CRISPR/Cas, the immune system of bacteria and archaea". Science. 327 (5962): 167–70. doi:10.1126/science.1179555. PMID\xa0'
                          '20056882.\n'
                          '\n'
                          '^ Bialk P, Rivera-Torres N, Strouse B, Kmiec EB (2015-06-08). "Regulation of Gene Editing Activity Directed by Single-Stranded Oligonucleotides and CRISPR/Cas9 Systems". '
                          'PloS One. 10 (6): e0129308. doi:10.1371/journal.pone.0129308. PMC\xa04459703. PMID\xa026053390.\n'
                          '\n'
                          '^ "Optimized CRISPR Design". crispr.mit.edu. Retrieved 2015-12-20.\n'
                          '\n'
                          '^ Carl Zimmerman (Oct 15, 2015). "Editing of Pig DNA May Lead to More Organs for People". NY Times.\n'
                          '\n'
                          '^ Hale CR, Majumdar S, Elmore J, Pfister N, Compton M, Olson S, Resch AM, Glover CV, Graveley BR, Terns RM, Terns MP (February 2012). "Essential features and rational '
                          'design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs". Molecular Cell. 45 (3): 292–302. doi:10.1016/j.molcel.2011.10.023. PMC\xa03278580. '
                          'PMID\xa022227116.\n'
                          '\n'
                          '^ Sorek R, Kunin V, Hugenholtz P (March 2008). "CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea". Nature Reviews. '
                          'Microbiology. 6 (3): 181–6. doi:10.1038/nrmicro1793. PMID\xa018157154.\n'
                          '\n'
                          '^ Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (February 2013). "Multiplex genome engineering using CRISPR/Cas '
                          'systems". Science. 339 (6121): 819–23. Bibcode:2013Sci...339..819C. doi:10.1126/science.1231143. PMC\xa03795411. PMID\xa023287718.\n'
                          '\n'
                          '^ Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (February 2013). "RNA-guided human genome engineering via Cas9". Science. 339 (6121): '
                          '823–6. Bibcode:2013Sci...339..823M. doi:10.1126/science.1232033. PMC\xa03712628. PMID\xa023287722.Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA '
                          '(September 2013). "Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis". Proceedings of the National Academy of Sciences of '
                          'the United States of America. 110 (39): 15644–9. Bibcode:2013PNAS..11015644H. doi:10.1073/pnas.1313587110.\n'
                          '\n'
                          '^ Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (January 2014). "Genome-scale CRISPR-Cas9 knockout '
                          'screening in human cells". Science. 343 (6166): 84–7. doi:10.1126/science.1247005. PMC\xa04089965. PMID\xa024336571.\n'
                          '\n'
                          '^ van Erp PB, Bloomer G, Wilkinson R, Wiedenheft B (June 2015). "The history and market impact of CRISPR RNA-guided nucleases". Current Opinion in Virology. 12: 85–90. '
                          'doi:10.1016/j.coviro.2015.03.011. PMID\xa025914022.\n'
                          '\n'
                          '^ Maggio I, Gonçalves MA (May 2015). "Genome editing at the crossroads of delivery, specificity, and fidelity". Trends in Biotechnology. 33 (5): 280–91. '
                          'doi:10.1016/j.tibtech.2015.02.011. PMID\xa025819765.\n'
                          '\n'
                          '^ Rath D, Amlinger L, Rath A, Lundgren M (October 2015). "The CRISPR-Cas immune system: biology, mechanisms and applications". Biochimie. 117: 119–28. '
                          'doi:10.1016/j.biochi.2015.03.025. PMID\xa025868999.\n'
                          '\n'
                          '^ a b Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV, Peters DT, Lu J, Baccei A, Siedlecki AM, Valerius MT, Musunuru K, '
                          'McNagny KM, Steinman TI, Zhou J, Lerou PH, Bonventre JV (23 October 2015). "Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent '
                          'epiblast spheroids". Nature Communications. 6: 8715. doi:10.1038/ncomms9715. PMID\xa026493500.\n'
                          '\n'
                          "^ Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL (December "
                          '2013). "Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome". The EMBO Journal. 32 (24): 3161–75. '
                          'doi:10.1038/emboj.2013.240. PMC\xa03981141. PMID\xa024213244.\n'
                          '\n'
                          '^ a b c d e f Science News Staff (December 17, 2015). "And Science\'s Breakthrough of the Year is …". news.sciencemag.org. Retrieved 2015-12-21.\n'
                          '\n'
                          '^ Citorik RJ, Mimee M, Lu TK (November 2014). "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases". Nature Biotechnology. 32 (11): 1141–5. '
                          'doi:10.1038/nbt.3011. PMID\xa025240928.\n'
                          '\n'
                          '^ Abrahimi P, Chang WG, Kluger MS, Qyang Y, Tellides G, Saltzman WM, Pober JS (July 2015). "Efficient gene disruption in cultured primary human endothelial cells by '
                          'CRISPR/Cas9". Circulation Research. 117 (2): 121–8. doi:10.1161/CIRCRESAHA.117.306290. PMID\xa025940550.\n'
                          '\n'
                          '^ Yong, Ed (2015-11-25). "The Revolutionary Gene-Editing Technique That Reveals Cancer\'s Weaknesses". The Atlantic. Retrieved 2016-02-21.\n'
                          '\n'
                          '^ "Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting '
                          'applications". Pubmed. 2016-03-04. PMID\xa026944702. Retrieved 2016-05-22.\n'
                          '\n'
                          '^ "Who Owns the Biggest Biotech Discovery of the Century? There\'s a bitter fight over the patents for CRISPR, a breakthrough new form of DNA editing". MIT Technology '
                          'Review. Retrieved 25 February 2015. CRISPR Patents Spark Fight to Control Genome Editing\n'
                          '\n'
                          '^ Fye, Shaan. "Genetic Rough Draft: Editas and CRISPR". The Atlas Business Journal. Retrieved 19 January 2016.\n'
                          '\n'
                          '^ "CRISPR Madness". GEN.\n'
                          '\n'
                          '^ Antonio Regalado for MIT Technology Review, March 5, 2015 Engineering the Perfect Baby\n'
                          '\n'
                          '^ Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J (March 2015). "Don\'t edit the human germ line". Nature. 519 (7544): 410–1. Bibcode:2015Natur.519..410L. '
                          'doi:10.1038/519410a. PMID\xa025810189.\n'
                          '\n'
                          '^ Wade, Nicholas (19 March 2015). "Scientists Seek Ban on Method of Editing the Human Genome". The New York Times. Retrieved 20 March 2015. The biologists writing in '
                          'Science support continuing laboratory research with the technique, and few if any scientists believe it is ready for clinical use.\n'
                          '\n'
                          '^ Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J (May 2015). "CRISPR/Cas9-mediated gene '
                          'editing in human tripronuclear zygotes". Protein & Cell. 6 (5): 363–72. doi:10.1007/s13238-015-0153-5. PMC\xa04417674. PMID\xa025894090.\n'
                          '\n'
                          '^ Kolata, Gina (23 April 2015). "Chinese Scientists Edit Genes of Human Embryos, Raising Concerns". The New York Times. Retrieved 24 April 2015.\n'
                          '\n'
                          '^ a b "Chinese scientists genetically modify human embryos". Nature. 22 April 2015.\n'
                          '\n'
                          '^ "International Summit on Gene Editing". National Academies of Sciences, Engineering, and Medicine. 3 December 2015. Retrieved 3 December 2015.\n'
                          '\n'
                          '^ Gallagher, James (1 February 2016). "Scientists get \'gene editing\' go-ahead". BBC News. BBC. Retrieved 1 February 2016.\n'
                          '\n'
                          '^ Cheng, Maria (1 February 2016). "Britain approves controversial gene-editing technique". AP News. Retrieved 1 February 2016.\n'
                          '\n'
                          '^ Talbot, Da\\vid (2016). "Precise Gene Editing in Plants/ 10 Breakthrough Technologies 2016". Massachusetts Institute of Technology. Retrieved 18 March 2016.\n'
                          '\n'
                          '^ Larson, Christina; Schaffer, Amanda (2014). "Genome Editing/ 10 Breakthrough Technologies 2014". Massachusetts Institute of Technology. Retrieved 18 March 2016.\n'
                          '\n'
                          '^ Huo Y, Nam KH, Ding F, Lee H, Wu L, Xiao Y, Farchione MD, Zhou S, Rajashankar K, Kurinov I, Zhang R, Ke A (September 2014). "Structures of CRISPR Cas3 offer mechanistic '
                          'insights into Cascade-activated DNA unwinding and degradation". Nature Structural & Molecular Biology. 21 (9): 771–7. doi:10.1038/nsmb.2875. PMC\xa04156918. PMID\xa0'
                          '25132177.',
                  'subsections': []},
                 {'name': 'Further reading',
                  'level': 1,
                  'parent': 'root',
                  'path': 'root|Further reading',
                  'text': 'CRISPR-Cas: A Laboratory Manual Edited by Jennifer Doudna, University of California, Berkeley; Prashant Mali, University of California, San Diego\n'
                          '\n'
                          'Sander JD, Joung JK (April 2014). "CRISPR-Cas systems for editing, regulating and targeting genomes". Nature Biotechnology. 32 (4): 347–55. doi:10.1038/nbt.2842. PMID\xa0'
                          '24584096.\n'
                          '\n'
                          'Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (January 2016). "Rationally engineered Cas9 nucleases with improved specificity". Science. 351 (6268): 84–8. '
                          'doi:10.1126/science.aad5227.\n'
                          '\n'
                          'Terns RM, Terns MP (March 2014). "CRISPR-based technologies: prokaryotic defense weapons repurposed". Trends in Genetics. 30 (3): 111–8. doi:10.1016/j.tig.2014.01.003. '
                          'PMID\xa024555991.\n'
                          '\n'
                          'Westra ER, Buckling A, Fineran PC (May 2014). "CRISPR-Cas systems: beyond adaptive immunity". Nature Reviews. Microbiology. 12 (5): 317–26. doi:10.1038/nrmicro3241. '
                          'PMID\xa024704746.\n'
                          '\n'
                          'Andersson AF, Banfield JF (May 2008). "Virus population dynamics and acquired virus resistance in natural microbial communities". Science. 320 (5879): 1047–50. '
                          'Bibcode:2008Sci...320.1047A. doi:10.1126/science.1157358. PMID\xa018497291.\n'
                          '\n'
                          'Hale C, Kleppe K, Terns RM, Terns MP (December 2008). "Prokaryotic silencing (psi)RNAs in Pyrococcus furiosus". Rna. 14 (12): 2572–9. doi:10.1261/rna.1246808. PMC\xa0'
                          '2590957. PMID\xa018971321.\n'
                          '\n'
                          'van der Ploeg JR (June 2009). "Analysis of CRISPR in Streptococcus mutans suggests frequent occurrence of acquired immunity against infection by M102-like bacteriophages". '
                          'Microbiology. 155 (Pt 6): 1966–76. doi:10.1099/mic.0.027508-0. PMID\xa019383692.\n'
                          '\n'
                          'van der Oost J, Brouns SJ (November 2009). "RNAi: prokaryotes get in on the act". Cell. 139 (5): 863–5. doi:10.1016/j.cell.2009.11.018. PMID\xa019945373.\n'
                          '\n'
                          'Karginov FV, Hannon GJ (January 2010). "The CRISPR system: small RNA-guided defense in bacteria and archaea". Molecular Cell. 37 (1): 7–19. '
                          'doi:10.1016/j.molcel.2009.12.033. PMC\xa02819186. PMID\xa020129051.\n'
                          '\n'
                          'Pul U, Wurm R, Arslan Z, Geissen R, Hofmann N, Wagner R (March 2010). "Identification and characterization of E. coli CRISPR-cas promoters and their silencing by H-NS". '
                          'Molecular Microbiology. 75 (6): 1495–512. doi:10.1111/j.1365-2958.2010.07073.x. PMID\xa020132443.\n'
                          '\n'
                          'Díez-Villaseñor C, Almendros C, García-Martínez J, Mojica FJ (May 2010). "Diversity of CRISPR loci in Escherichia coli". Microbiology. 156 (Pt 5): 1351–61. '
                          'doi:10.1099/mic.0.036046-0. PMID\xa020133361.\n'
                          '\n'
                          'Deveau H, Garneau JE, Moineau S (2010). "CRISPR/Cas system and its role in phage-bacteria interactions". Annual Review of Microbiology. 64: 475–93. '
                          'doi:10.1146/annurev.micro.112408.134123. PMID\xa020528693.\n'
                          '\n'
                          'Koonin EV, Makarova KS (December 2009). "CRISPR-Cas: an adaptive immunity system in prokaryotes". F1000 Biology Reports. 1: 95. doi:10.3410/B1-95. PMC\xa02884157. PMID\xa0'
                          '20556198.\n'
                          '\n'
                          '"The age of the red pen". The Economist. August 22, 2015. ISSN\xa00013-0613. Retrieved 2015-08-25.\n'
                          '\n'
                          'Lander ES (January 2016). "The Heroes of CRISPR". Cell. 164 (1–2): 18–28. doi:10.1016/j.cell.2015.12.041. PMID\xa026771483. \n'
                          '\n'
                          'v\n'
                          '\n'
                          't\n'
                          '\n'
                          'e\n'
                          '\n'
                          '1996: HIV understanding\n'
                          '\n'
                          '1997: Dolly the sheep\n'
                          '\n'
                          '1998: Accelerating universe\n'
                          '\n'
                          '1999: Stem cell\n'
                          '\n'
                          '2000: Whole genome sequencing\n'
                          '\n'
                          '2001: Nanocircuits or Molecular circuit\n'
                          '\n'
                          '2002: RNA interference\n'
                          '\n'
                          '2003: Dark energy\n'
                          '\n'
                          '2004: Spirit rover\n'
                          '\n'
                          '2005: Evolution in action\n'
                          '\n'
                          '2006: Poincaré conjecture proof\n'
                          '\n'
                          '2007: Human genetic variation\n'
                          '\n'
                          '2008: Cellular reprogramming\n'
                          '\n'
                          '2009: Ardipithecus ramidus\n'
                          '\n'
                          '2010: First quantum machine\n'
                          '\n'
                          '2011: HPTN 052 clinical trial\n'
                          '\n'
                          '2012: Higgs boson discovery\n'
                          '\n'
                          '2013: Cancer immunotherapy\n'
                          '\n'
                          '2014: Rosetta comet mission\n'
                          '\n'
                          '2015: CRISPR genome-editing method\n'
                          '\n'
                          '2016: First observation of gravitational waves\n'
                          '\n'
                          '2017: GW170817 (neutron star merger)\n'
                          '\n'
                          '2018: Single cell sequencing\n'
                          '\n'
                          '2019: First image of black hole',
                  'subsections': []}]}

====================================================================================================
History Section

{'name': 'History',
 'level': 1,
 'parent': 'root',
 'path': 'root|History',
 'text': 'Clustered repeats were first described in 1987 for the bacterium Escherichia coli by Osaka University researcher Yoshizumi Ishino, but at that time their function was not known.[19] The '
         'repeats were observed independently by Spanish researcher Francisco Mojica in 1993.[20] He later named them short regularly spaced repeats (SRSR) after he found them in many other '
         'microbes.[21] In 2000, similar repeats were identified in other bacteria and archaea.[21] SRSR was renamed CRISPR in 2002 after a suggestion from Mojica.[20][22] \n'
         '\n'
         'CRISPR was asserted to be responsible for the generation of adaptive immunity in microbes.[23] The paper describing this idea was initially rejected by high-profile journals.[20] Papers '
         'proposing similar hypotheses by Gilles Vergnaud and independently by Alexander Bolotin initially suffered similar fates.[20][24][25]\n'
         '\n'
         'A set of genes was found to be associated with CRISPR repeats and was named Cas, or CRISPR-associated genes. The Cas genes encode putative nuclease or helicase proteins, which are enzymes '
         'that can cut or unwind DNA, respectively.[22] \n'
         '\n'
         'In 2005, three independent research groups showed that some CRISPR spacers are derived from phage DNA and extrachromosomal DNA such as plasmids.[26][27][28] In effect, the spacers are '
         'fragments of DNA gathered from viruses that previously tried to attack the cell. The source of the spacers was a sign that the CRISPR/cas system could have a role in adaptive immunity in '
         'bacteria.[1][29] \n'
         '\n'
         'Koonin and colleagues proposed that spacers serve as a template for RNA molecules, analogous to the RNA interference system used by eukaryotic cells.[30]\n'
         '\n'
         "In 2007, Barrangou, Horvath (food industry scientists at Danisco), and Moineau's group at Université Laval (Canada) showed that they could use spacer DNA to alter the resistance of "
         'Streptococcus thermophilus to phage attack.[30]\n'
         '\n'
         'Feng Zhang and colleagues first described genome editing in human and mouse cell culture using CRISPR/Cas systems.[31][32] It has since been used in a wide range of organisms, including '
         "baker's yeast (Saccharomyces cerevisiae),[33] zebrafish (D. rerio),[34] fruit flies (Drosophila melanogaster),[35] axolotl (A. mexicanum),[36] nematodes,(C. elegans),[37] plants,[38] "
         'mice,[39] monkeys[40] and human embryos.[41]\n'
         '\n'
         'CRISPR has been modified to make programmable transcription factors that allow scientists to target and activate or silence specific genes.[42]\n'
         '\n'
         'Libraries of tens of thousands of guide RNAs are available.[30]',
 'subsections': [{'name': 'Cas9',
                  'level': 2,
                  'parent': 'History',
                  'path': 'root|History|Cas9',
                  'text': 'In 2012, Jennifer Doudna and Emmanuelle Charpentier first showed CRISPR to work as a genome-engineering and editing tool in bacterial cell cultures.[43][44][better\xa0'
                          'source\xa0needed] The team had independently been exploring CRISPR-associated proteins to learn how bacteria use spacers in their immune defenses.[45][better\xa0source\xa0'
                          'needed] They jointly studied a simpler CRISPR system that relies on a protein called Cas9. They found that bacteria respond to an invading phage by transcribing spacers '
                          'and palindromic DNA into a long RNA molecule. The cell then uses tracrRNA and Cas9 to cut this long RNA molecule into pieces called crRNAs.[30]\n'
                          '\n'
                          "Cas9 is a nuclease, an enzyme specialized for cutting DNA. It has two active cutting sites (HNH and RuvC), one for each strand of the DNA's double helix. Doudna and "
                          "Charpentier demonstrated that they could disable one or both sites while preserving Cas9's ability to home in on its target DNA. In 2012, a group including both Doudna and "
                          'Charpentier combined tracrRNA and spacer RNA into a "single-guide RNA" molecule that, mixed with Cas9, could find and cut the correct DNA targets. Their study proposed '
                          'that such synthetic guide RNAs could be used for gene editing.[43]',
                  'subsections': []},
                 {'name': 'Cpf1',
                  'level': 2,
                  'parent': 'History',
                  'path': 'root|History|Cpf1',
                  'text': 'In 2015, the nuclease Cpf1 was discovered in the CRISPR/Cpf1 system of Francisella novicida.[12][13]',
                  'subsections': []},
                 {'name': 'Predecessors',
                  'level': 2,
                  'parent': 'History',
                  'path': 'root|History|Predecessors',
                  'text': 'In the early 2000s, researchers developed zinc finger nucleases, synthetic proteins whose DNA-binding domains enable them to create double-stranded breaks in DNA at '
                          'specific points. In 2010, synthetic nucleases called TALENs provided an easier way to target a double-stranded break to a specific location on the DNA strand. Both zinc '
                          'finger nucleases and TALENs require the creation of a custom protein for each targeted DNA sequence, which is a more difficult and time-consuming process than that for '
                          'guide RNAs. CRISPRs are much easier to design because the process requires making only a short RNA sequence.[46]',
                  'subsections': []}]}

Titles and Authors in History Section

//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg
[('mw-parser-output citecitation{font-style:inherit}mw-parser-output citation q{quotes:"\\"""\\"""\'""\'"}mw-parser-output id-lock-free', 'a'), ('mw-parser-output citation cs1-lock-free', 'a{background:linear-gradient')]

CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea
[('Marraffini', 'LA'), ('Sontheimer', 'EJ')]

The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats
[('Grissa', 'I'), ('Vergnaud', 'G'), ('Pourcel', 'C')]

Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product
[('Ishino', 'Y'), ('Shinagawa', 'H'), ('Makino', 'K'), ('Amemura', 'M'), ('Nakata', 'A')]

The Heroes of CRISPR
[('Lander', 'ES')]

Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria
[('Mojica', 'FJ'), ('Díez-Villaseñor', 'C'), ('Soria', 'E'), ('Juez', 'G')]

Identification of genes that are associated with DNA repeats in prokaryotes
[('Jansen', 'R'), ('Embden', 'JD'), ('Gaastra', 'W'), ('Schouls', 'LM')]

Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements
[('Mojica', 'FJ'), ('Díez-Villaseñor', 'C'), ('García-Martínez', 'J'), ('Soria', 'E')]

CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies
[('Pourcel', 'C'), ('Salvignol', 'G'), ('Vergnaud', 'G')]

Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
[('Bolotin', 'A'), ('Quinquis', 'B'), ('Sorokin', 'A'), ('Ehrlich', 'SD')]

CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies
[('Pourcel', 'C'), ('Salvignol', 'G'), ('Vergnaud', 'G')]

Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements
[('Mojica', 'FJ'), ('Díez-Villaseñor', 'C'), ('García-Martínez', 'J'), ('Soria', 'E')]

Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
[('Bolotin', 'A'), ('Quinquis', 'B'), ('Sorokin', 'A'), ('Ehrlich', 'SD')]

What history tells us XXXVII. CRISPR-Cas: The discovery of an immune system in prokaryotes
[('Morange', 'M')]

The CRISPR craze
[('Pennisi', 'E')]

Multiplex genome engineering using CRISPR/Cas systems
[('Cong', 'L'), ('Ran', 'FA'), ('Cox', 'D'), ('Lin', 'S'), ('Barretto', 'R'), ('Habib', 'N'), ('Hsu', 'PD'), ('Wu', 'X'), ('Jiang', 'W'), ('Marraffini', 'LA'), ('Zhang', 'F')]

, CRISPR-CAS Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes, retrieved 2016-04-26
[]

Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems
[('DiCarlo', 'JE'), ('Norville', 'JE'), ('Mali', 'P'), ('Rios', 'X'), ('Aach', 'J'), ('Church', 'GM')]

Efficient genome editing in zebrafish using a CRISPR-Cas system
[('Hwang', 'WY'), ('Fu', 'Y'), ('Reyon', 'D'), ('Maeder', 'ML'), ('Tsai', 'SQ'), ('Sander', 'JD'), ('Peterson', 'RT'), ('Yeh', 'JR'), ('Joung', 'JK')]

Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease
[('Gratz', 'SJ'), ('Cummings', 'AM'), ('Nguyen', 'JN'), ('Hamm', 'DC'), ('Donohue', 'LK'), ('Harrison', 'MM'), ('Wildonger', 'J'), ("O'Connor-Giles", 'KM')]

Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided nuclease
[('Flowers', 'GP'), ('Timberlake', 'AT'), ('McLean', 'KC'), ('Monaghan', 'JR'), ('Crews', 'CM')]

Heritable genome editing in C. elegans via a CRISPR-Cas9 system
[('Friedland', 'AE'), ('Tzur', 'YB'), ('Esvelt', 'KM'), ('Colaiácovo', 'MP'), ('Church', 'GM'), ('Calarco', 'JA')]

Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, sorghum and rice
[('Jiang', 'W'), ('Zhou', 'H'), ('Bi', 'H'), ('Fromm', 'M'), ('Yang', 'B'), ('Weeks', 'DP')]

One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering
[('Wang', 'H'), ('Yang', 'H'), ('Shivalila', 'CS'), ('Dawlaty', 'MM'), ('Cheng', 'AW'), ('Zhang', 'F'), ('Jaenisch', 'R')]

Targeted genome editing in primate embryos
[('Guo', 'X'), ('Li', 'XJ')]

Biotechnology. A prudent path forward for genomic engineering and germline gene modification
[('Baltimore', 'D'), ('Berg', 'P'), ('Botchan', 'M'), ('Carroll', 'D'), ('Charo', 'RA'), ('Church', 'G'), ('Corn', 'JE'), ('Daley', 'GQ'), ('Doudna', 'JA'), ('Fenner', 'M'), ('Greely', 'HT'), ('Jinek', 'M'), ('Martin', 'GS'), ('Penhoet', 'E'), ('Puck', 'J'), ('Sternberg', 'SH'), ('Weissman', 'JS'), ('Yamamoto', 'KR')]

CRISPR interference (CRISPRi) for sequence-specific control of gene expression
[('Larson', 'MH'), ('Gilbert', 'LA'), ('Wang', 'X'), ('Lim', 'WA'), ('Weissman', 'JS'), ('Qi', 'LS')]

